{"id":"olaparib","rwe":[{"pmid":"41900138","year":"2026","title":"Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41900056","year":"2026","title":"Four New Menadione Thioderivatives, Potential Antineoplastic Candidates: In Silico and PARP-1 Inhibition Studies.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41899447","year":"2026","title":"MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling.","finding":"","journal":"Current issues in molecular biology","studyType":"Clinical Study"},{"pmid":"41899441","year":"2026","title":"MSTN and TCF12 as Candidate Immunometabolic Signatures in Glioma-Associated Foam Cells: Insights from Integrated Multi-Omics Analysis.","finding":"","journal":"Current issues in molecular biology","studyType":"Clinical Study"},{"pmid":"41898642","year":"2026","title":"The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"}],"_fda":{"id":"0142c57f-6211-4638-8c48-c215686871b8","set_id":"741ff3e3-dc1a-45a6-84e5-2481b27131aa","openfda":{"nui":["N0000191623","N0000191622"],"unii":["WOH1JD9AR8"],"route":["ORAL"],"rxcui":["1942482","1942485","1942487","1942489"],"spl_id":["0142c57f-6211-4638-8c48-c215686871b8"],"brand_name":["Lynparza"],"spl_set_id":["741ff3e3-dc1a-45a6-84e5-2481b27131aa"],"package_ndc":["0310-0668-60","0310-0668-12","0310-0668-95","0310-0679-60","0310-0679-12","0310-0679-95","0310-0569-60","0310-0569-12","0310-0578-60","0310-0578-12"],"product_ndc":["0310-0569","0310-0668","0310-0679","0310-0578"],"generic_name":["OLAPARIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["OLAPARIB"],"pharm_class_epc":["Poly(ADP-Ribose) Polymerase Inhibitor [EPC]"],"pharm_class_moa":["Poly(ADP-Ribose) Polymerase Inhibitors [MoA]"],"manufacturer_name":["AstraZeneca Pharmaceuticals LP"],"application_number":["NDA208558"],"is_original_packager":[true]},"version":"38","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1) ] , Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily (see Data ). Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies. Data Animal Data In a fertility and early embryonic development study in female rats, olaparib was administered orally for 14 days before mating through to Day 6 of pregnancy, which resulted in increased post-implantation loss at a dose level of 15 mg/kg/day (with maternal systemic exposures approximately 7% of the human exposure (AUC 0-24h ) at the recommended dose). In an embryo-fetal development study, pregnant rats received oral doses of 0.05 and 0.5 mg/kg/day olaparib during the period of organogenesis. A dose of 0.5 mg/kg/day (with maternal systemic exposures approximately 0.18% of human exposure (AUC 0-24h ) at the recommended dose) caused embryo-fetal toxicities including increased post-implantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital), and diaphragm (hernia). Additional abnormalities or variants included incomplete or absent ossification (vertebrae/sternebrae, ribs, limbs) and other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter, and umbilical artery. Some findings noted above in the eyes, ribs, and ureter were observed at a dose of 0.05 mg/kg/day olaparib at lower incidence."],"description":["11 DESCRIPTION Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one. The empirical molecular formula for Lynparza is C 24 H 23 FN 4 O 3 and the relative molecular mass is 434.46. It has the following chemical structure: Olaparib is a crystalline solid, is non-chiral and shows pH-independent low solubility across the physiological pH range. Lynparza (olaparib) tablets for oral use contain 100 mg or 150 mg of olaparib. Inactive ingredients in the tablet core are copovidone, mannitol, colloidal silicon dioxide, and sodium stearyl fumarate. The tablet coating consists of hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow, and ferrosoferric oxide (150 mg tablet only). chemical structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Lynparza is available as 150 mg and 100 mg tablets. • 150 mg tablets: green to green/grey, oval, bi-convex, film-coated tablet, with debossment ‘OP150’ on one side and plain on the reverse, are available in: ∘ Bottles of 60 tablets (NDC 0310-0679-60) and ∘ Bottles of 120 tablets (NDC 0310-0679-12). • 100 mg tablets: yellow to dark yellow, oval, bi-convex, film-coated tablet, with debossment ‘OP100’ on one side and plain on the reverse, are available in: ∘ Bottles of 60 tablets (NDC 0310-0668-60) and ∘ Bottles of 120 tablets (NDC 0310-0668-12). Store at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Store in original bottle to protect from moisture."],"spl_medguide":["Medication Guide Lynparza ® (Lin-par-zah) (olaparib) tablets What is the most important information I should know about Lynparza? Lynparza may cause serious side effects, including: • Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Lynparza. MDS or AML may lead to death. Symptoms of low blood cell counts are common during treatment with Lynparza, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include: ∘ weakness ∘ weight loss ∘ fever ∘ frequent infections ∘ blood in urine or stool ∘ shortness of breath ∘ feeling very tired ∘ bruising or bleeding more easily Your healthcare provider will do blood tests to check your blood cell counts: ∘ before treatment with Lynparza ∘ every month during treatment with Lynparza ∘ weekly if you have low blood cell counts that last a long time. • Lung problems (Pneumonitis). Lynparza can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. • Blood clots (Venous Thromboembolism, [VTE]). Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis), or a clot in the lungs (pulmonary embolism, [PE]) which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine. • Liver problems, including Drug-Induced Liver Injury (DILI). People taking Lynparza may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with Lynparza. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or “tea-colored” urine, or yellowing of your skin or the whites of your eyes (jaundice). Your healthcare provide may change your dose, temporarily stop, or permanently stop treatment with Lynparza if you get certain side effects. See “What are the possible side effects of LYNPARZA?” for more information about side effects. What is Lynparza? Lynparza is a prescription medicine used to treat adults who have: • ovarian, fallopian tube, or primary peritoneal cancer: ∘ that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Lynparza is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. ∘ in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD) positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. Lynparza is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. ∘ that has come back and has a certain type of inherited or acquired abnormal BRCA gene. Lynparza is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy. • human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene: ∘ with a high risk of recurrence. Lynparza is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor. ∘ that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormonal therapy is not the right treatment for you. • pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. Lynparza is used as maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy. • metastatic castration-resistant prostate cancer (mCRPC): ∘ with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. Lynparza is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone. ∘ with a certain type of abnormal BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. Lynparza is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone. Your healthcare provider will perform a test to make sure that Lynparza is right for you. It is not known if Lynparza is safe and effective in children. Before taking Lynparza, tell your healthcare provider about all of your medical conditions, including if you: • have lung or breathing problems • have kidney problems • are pregnant, become pregnant, or plan to become pregnant. Lynparza can harm your unborn baby and may cause loss of pregnancy (miscarriage). Females who are able to become pregnant: ∘ Your healthcare provider may do a pregnancy test before you start treatment with Lynparza. ∘ You should use effective birth control (contraception) during treatment with Lynparza and for 6 months after the last dose of Lynparza. Talk to your healthcare provider about birth control methods that may be right for you. ∘ Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with Lynparza. Males with female partners who are pregnant or able to become pregnant: ∘ You should use effective contraception during treatment with Lynparza and for 3 months after the last dose of Lynparza. ∘ Do not donate sperm during treatment with Lynparza and for 3 months after your last dose. • are breastfeeding or plan to breastfeed. It is not known if Lynparza passes into your breast milk. Do not breastfeed during treatment with Lynparza and for 1 month after receiving the last dose of Lynparza. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Lynparza and certain other medicines may affect how Lynparza works and may cause side effects. How should I take Lynparza? • Take Lynparza tablets exactly as your healthcare provider tells you. • Your healthcare provider will decide how long you stay on treatment. • Do not change your dose or stop taking Lynparza unless your healthcare provider tells you to. • Take Lynparza by mouth 2 times a day with or without food. • Each dose should be taken about 12 hours apart. • Swallow Lynparza tablets whole. Do not chew, crush, dissolve, or divide the tablets. • If you are taking Lynparza for early breast cancer and you have HR‑positive disease, you should continue to take hormonal therapy during your treatment with Lynparza. • If you are taking Lynparza for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with Lynparza unless you have had a surgery to remove both of your testicles (surgical castration) to lower the amount of testosterone in your body. • If you miss a dose of Lynparza, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose. • If you take too much Lynparza, call your healthcare provider or go to the nearest hospital emergency room right away. What should I avoid while taking Lynparza? Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with Lynparza since they may increase the level of Lynparza in your blood. What are the possible side effects of Lynparza? Lynparza may cause serious side effects. • See “What is the most important information I should know about Lynparza?” The most common side effects of Lynparza when used alone are: • tiredness or weakness • low red blood cell counts • diarrhea • loss of appetite • headache • changes in the way food tastes • cough • low white blood cell counts • shortness of breath • dizziness • indigestion or heartburn • low platelet counts The most common side effects of Lynparza when used in combination with bevacizumab are: • tiredness or weakness • low red blood cell counts • diarrhea • low white blood cell counts • urinary tract infection • headache The most common side effects of Lynparza when used in combination with abiraterone and prednisone or prednisolone are: • low red blood cell counts • tiredness or weakness • diarrhea • loss of appetite • low white blood cell counts • dizziness • stomach-area (abdominal) pain Nausea or vomiting is common during treatment with Lynparza. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms. These are not all of the possible side effects of Lynparza. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store Lynparza? • Store Lynparza at room temperature, between 68°F to 77°F (20°C to 25°C). • Store Lynparza in the original bottle to protect it from moisture. Keep Lynparza and all medicines out of reach of children. General information about the safe and effective use of Lynparza. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Lynparza for a condition for which it was not prescribed. Do not give Lynparza to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Lynparza that is written for health professionals. What are the ingredients in Lynparza? Active ingredient: olaparib Inactive ingredients: Tablet contains: copovidone, mannitol, colloidal silicon dioxide and sodium stearyl fumarate Tablet coating contains: hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow and ferrosoferric oxide (150 mg tablet only) Lynparza is a registered trademark of the AstraZeneca group of companies. © AstraZeneca 2025 Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 For more information, call 1-800-236-9933 or go to www.Lynparza.com . This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 07/2025"],"geriatric_use":["8.5 Geriatric Use Of the 2901 patients with advanced solid tumors who received Lynparza as a single agent, 680 (23%) patients were aged ≥65 years, and this included 206 (7%) patients who were aged ≥75 years. Thirteen (0.4%) patients were aged ≥85 years. Of the 535 patients with advanced solid tumors who received Lynparza tablets 300 mg orally twice daily in combination with bevacizumab (PAOLA-1), 204 (38%) patients were aged ≥65 years, and this included 31 (6%) patients who were aged ≥75 years. Of the 398 patients with advanced solid tumors who received Lynparza tablets 300 mg orally twice daily in combination with abiraterone and prednisone or prednisolone (PROpel), 268 (67%) patients were aged ≥65 years, and this included 95 (24%) patients who were aged ≥75 years. No overall differences in the safety or effectiveness of Lynparza were observed between these patients and younger patients."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of Lynparza have not been established in pediatric patients."],"effective_time":"20250710","clinical_studies":["14 CLINICAL STUDIES 14.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer The efficacy of Lynparza was evaluated in SOLO-1 (NCT01844986), a randomized (2:1), double-blind, placebo-controlled, multi-center trial in patients with BRCA -mutated advanced ovarian, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy. Patients were randomized to receive Lynparza tablets 300 mg orally twice daily or placebo. Treatment was continued for up to 2 years or until disease progression or unacceptable toxicity; however, patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider could derive further benefit from continuous treatment, could be treated beyond 2 years. Randomization was stratified by response to first-line platinum-based chemotherapy (complete or partial response). The major efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. A total of 391 patients were randomized, 260 to Lynparza and 131 to placebo. The median age of patients treated with Lynparza was 53 years (range: 29 to 82) and 53 years (range: 31 to 84) among patients on placebo. The ECOG performance status (PS) was 0 in 77% of patients receiving Lynparza and 80% of patients receiving placebo. Of all patients, 82% were White, 36% were enrolled in the U.S. or Canada, and 82% were in complete response to their most recent platinum-based regimen. The majority of patients (n=389) had germline BRCA mutation (g BRCA m), and 2 patients had somatic BRCA m (s BRCA m). Of the 391 patients randomized in SOLO-1, 386 were retrospectively or prospectively tested with a Myriad BRACAnalysis test and 383 patients were confirmed to have deleterious or suspected deleterious g BRCA m status; 253 were randomized to the Lynparza arm and 130 to the placebo arm. Two out of 391 patients randomized in SOLO-1 were confirmed to have s BRCA m based on an investigational Foundation Medicine tissue test. SOLO-1 demonstrated a statistically significant improvement in investigator-assessed PFS for Lynparza compared to placebo. Results from a blinded independent review were consistent. At the time of the analysis of PFS, overall survival (OS) data were not mature (21% of patients had died). Efficacy results are presented in Table 18 and Figure 1. Table 18 Efficacy Results - SOLO-1 (Investigator Assessment) Lynparza tablets (n=260) Placebo (n=131) Progression-Free Survival Median follow-up of 41 months in both treatment arms. Number of events (%) 102 (39%) 96 (73%) Median, months NR 13.8 Hazard ratio A value <1 favors Lynparza. Hazard ratio from a Cox proportional hazards model including response to previous platinum chemotherapy (complete response versus partial response) as a covariate. (95% CI) 0.30 (0.23, 0.41) p-value The p-value is derived from a stratified log-rank test. <0.0001 NR not reached; CI Confidence Interval. Figure 1 Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival - SOLO-1 Figure 1 14.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab PAOLA-1 (NCT02477644) was a randomized, double-blind, placebo-controlled, multi-center trial that compared the efficacy of Lynparza in combination with bevacizumab versus placebo/bevacizumab for the maintenance treatment of advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer following first-line platinum-based chemotherapy and bevacizumab. Randomization was stratified by first-line treatment outcome (timing and outcome of cytoreductive surgery and response to platinum-based chemotherapy) and t BRCA m status, determined by prospective local testing. All available clinical samples were retrospectively tested with Myriad myChoice ® CDx. Patients were required to have no evidence of disease (NED) due to complete surgical resection, or who were in complete response (CR), or partial response (PR) following completion of first-line platinum-containing chemotherapy and bevacizumab. Patients were randomized (2:1) to receive Lynparza tablets 300 mg orally twice daily in combination with bevacizumab (n=537) 15 mg/kg every three weeks or placebo/bevacizumab (n=269). Patients continued bevacizumab in the maintenance setting and started treatment with Lynparza after a minimum of 3 weeks and up to a maximum of 9 weeks following completion of their last dose of chemotherapy. Lynparza treatment was continued for up to 2 years or until progression of the underlying disease or unacceptable toxicity. Patients who in the opinion of the treating physician could derive further benefit from continuous treatment could be treated beyond 2 years. Treatment with bevacizumab was for a total of up to 15 months, including the period given with chemotherapy and given as maintenance. The major efficacy outcome measure was investigator-assessed PFS evaluated according to RECIST, version 1.1. An additional efficacy endpoint was overall survival (OS). A statistically significant difference in PFS was observed in the intent-to-treat (ITT) population. Planned exploratory analyses of PFS and OS were conducted in patients with known HRD status. The PFS hazard ratio (HR) for patients with HRD-negative tumors (277/806; 34%) was 1.00 (95% CI: 0.75, 1.34) and the OS HR was 1.18 (95% CI: 0.87, 1.60) indicating that the clinical benefit was primarily attributed to the results seen in the HRD-positive population. Efficacy results in patients with HRD-positive tumors are summarized in Table 19, Figure 2, and Figure 3. Among the 387 patients (48%) with HRD-positive tumors identified post-randomization using the Myriad myChoice® HRD Plus tumor test the median age was 58 years in both arms (range 32-82). Ovarian cancer was the primary tumor type in 87% of patients in both arms. Ninety five percent (95%) were serous histological type. The ECOG performance score was 0 in 75% of patients and 1 in 24% of patients. All patients had received first-line platinum-based therapy and bevacizumab. First-line treatment outcomes at screening indicated that patients had no evidence of disease with complete macroscopic resection at initial debulking surgery (36%), no evidence of disease/CR with complete macroscopic resection at interval debulking surgery (29%, both arms), no evidence of disease/CR in patients who had either incomplete resection (at initial or interval debulking surgery) or no debulking surgery (16%, both arms) and patients with a partial response (19%, both arms). Sixty-two (62%) of patients in the Lynparza/bevacizumab arm and 58% of patients in placebo/bevacizumab arm had tumors with a deleterious BRCA mutation. Patients were not restricted by the surgical outcome with 67% having complete cytoreduction at initial or interval debulking surgery and 33% having residual macroscopic disease. Table 19 Efficacy Results - PAOLA-1 (HRD-positive status, Investigator Assessment) Lynparza/bevacizumab (n=255) Placebo/bevacizumab (n=132) Progression-Free Survival Results from a blinded independent review of PFS were consistent with those from investigator-assessed PFS Number of events (%) 87 (34%) 92 (70%) Median, months 37.2 17.7 Hazard ratio The analysis was performed using an unstratified Cox proportional hazards model. (95% CI) 0.33 (0.25, 0.45) Overall Survival Based on final OS subgroup analysis. Number of events (%) 93 (36%) 69 (52%) Median, months 75.2 57.3 Hazard ratio† (95% CI) 0.62 (0.45, 0.85) CI Confidence interval. Figure 2 Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival – PAOLA-1 (HRD-positive status) Figure 3 Kaplan-Meier Curves of Overall Survival – PAOLA-1 (HRD-positive status)* * Based on final OS subgroup analysis. Figure 2 figure-3 14.3 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer The efficacy of Lynparza was evaluated in SOLO-2 (NCT01874353), a randomized (2:1) double-blind, placebo-controlled trial in patients with BRCA m ovarian, fallopian tube, or primary peritoneal cancer who were in response to platinum-based therapy. Patients were randomized to Lynparza tablets 300 mg orally twice daily or placebo until unacceptable toxicity or progressive disease. Randomization was stratified by response to last platinum chemotherapy (complete versus partial) and time to disease progression in the penultimate platinum-based chemotherapy prior to enrollment (6-12 months versus >12 months). All patients had received at least two prior platinum-containing regimens and were in response (complete or partial) to their most recent platinum-based regimen. The major efficacy outcome measure was investigator-assessed PFS evaluated according to RECIST, version 1.1. An additional efficacy outcome measure was OS. A total of 295 patients were randomized, 196 to Lynparza and 99 to placebo. The median age of patients treated with Lynparza was 56 years (range: 28 to 83) and 56 years (range: 39 to 78) among patients treated with placebo. The ECOG PS was 0 in 83% of patients receiving Lynparza and 78% of patients receiving placebo. Of all patients, 89% were White, 17% were enrolled in the U.S. or Canada, 47% were in complete response to their most recent platinum-based regimen, and 40% had a progression-free interval of 6-12 months since their penultimate platinum regimen. Prior bevacizumab therapy was reported for 17% of those treated with Lynparza and 20% of those receiving placebo. Approximately 44% of patients on the Lynparza arm and 37% on placebo had received three or more lines of platinum-based treatment. All (100%) patients enrolled had g BRCA mutations. All patients had a deleterious or suspected deleterious germline BRCA mutation as detected either by a local test (n=236) or central Myriad CLIA test (n=59), subsequently confirmed by BRACAnalysis CDx ® (n=286). SOLO-2 demonstrated a statistically significant improvement in investigator-assessed PFS in patients randomized to Lynparza as compared with placebo. Results from a blinded independent review were consistent. The final analysis of OS did not reach statistical significance. Efficacy results are presented in Table 20 and Figures 4 and 5. Table 20 Efficacy Results - SOLO-2 (Investigator Assessment) Lynparza tablets (n=196) Placebo (n=99) Progression-Free Survival Number of events (%) 107 (55%) 80 (81%) Median, months 19.1 5.5 Hazard ratio Hazard ratio from a Cox proportional hazards model including response to last platinum chemotherapy (complete response versus partial response) and time to disease progression in the penultimate platinum-based chemotherapy prior to enrollment (6-12 month versus >12 months) as covariates. (95% CI) 0.30 (0.22, 0.41) p-value The p-value is derived from a stratified log-rank test. <0.0001 Overall Survival Number of events (%) 116 (59) 65 (66) Median, months 51.7 38.8 Hazard ratio (95% CI) 0.74 (0.54, 1.00) p-value 0.0537 Figure 4 Kaplan-Meier Curves of Investigator-Assessed Progression-Free Survival – SOLO-2 Figure 5 Kaplan-Meier Curves of Overall Survival – SOLO-2 Figure 3 Figure 4 14.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer The efficacy of Lynparza was evaluated in OlympiA (NCT02032823), a randomized (1:1), double-blind, placebo-controlled, international study in patients with gBRCAm HER2-negative high risk early breast cancer who had completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. Patients were randomized to receive Lynparza tablets 300 mg orally twice daily or placebo. Treatment was continued for up to 1 year, or until disease recurrence, or unacceptable toxicity. Patients were required to have completed at least 6 cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes or both. Prior platinum for previous cancer (e.g., ovarian) or as adjuvant or neoadjuvant treatment for breast cancer was allowed. Patients with high-risk early breast cancer were defined as follows: • patients who received prior neoadjuvant chemotherapy: patients with either triple negative breast cancer (TNBC) or hormone receptor positive breast cancer must have had residual invasive cancer in the breast and/or the resected lymph nodes (non-pathologic complete response) at the time of surgery. Additionally, patients with hormone receptor positive breast cancer must have had a score of ≥3 based on pre-treatment clinical and post-treatment pathologic stage (CPS), estrogen receptor (ER) status, and histologic grade as shown in Table 21. Table 21 Early Breast Cancer Stage, Receptor Status, and Grade Scoring Requirements for Study Enrollment Total score of ≥3 required for patients with hormone receptor positive breast cancer. Stage/feature Points Clinical Stage (pre-treatment) I/IIA 0 IIB/IIIA 1 IIIB/IIIC 2 Pathologic Stage (post-treatment) 0/I 0 IIA/IIB/IIIA/IIIB 1 IIIC 2 Receptor status ER positive 0 ER negative 1 Nuclear grade Nuclear grade 1-2 0 Nuclear grade 3 1 • patients who received prior adjuvant chemotherapy: patients with TNBC must have had node positive disease or node negative disease with a ≥2cm primary tumor; patients with hormone receptor positive, HER2-negative breast cancer must have had ≥4 pathologically confirmed positive lymph nodes. Randomization was stratified by hormone receptor status (hormone receptor positive versus triple negative), by prior neoadjuvant versus adjuvant chemotherapy, and by prior platinum use for breast cancer (yes versus no). The major efficacy outcome measure was invasive disease free survival (IDFS), defined as the time from randomization to date of first recurrence, where recurrence is defined as invasive loco-regional, distant recurrence, contralateral invasive breast cancer, new cancer or death from any cause. An additional efficacy outcome measure was OS. A total of 1836 patients were randomized, 921 to Lynparza and 915 to placebo. Demographic and baseline characteristics were well balanced between arms. The median age was 42 years. Sixty-seven percent (67%) of patients were White, 29% were Asian, and 3% were Black. Three percent (3%) of patients were Hispanic or Latino. Two patients (0.2%) in the Lynparza arm and four patients (0.4%) in the placebo arm were male. Sixty-one percent (61%) of patients were pre-menopausal. Eighty-nine percent (89%) of patients were ECOG performance status 0 and 11% ECOG PS 1. Eighty-two percent (82%) of patients had TNBC and 18% had hormone receptor-positive disease. Fifty percent (50%) of patients had received prior neoadjuvant and 50% received prior adjuvant chemotherapy. Ninety-four percent (94%) of patients received anthracycline and taxane chemotherapy. Twenty-six (26%) of patients overall had received prior platinum for breast cancer. Ninety percent (90%) of patients with hormone receptor positive breast cancer received concurrent endocrine therapy. Patients enrolled based on local gBRCA test results provided a sample for retrospective confirmatory central testing with BRACAnalysis®. Out of 1836 patients enrolled into OlympiA, 1623 were confirmed as gBRCAm by Myriad BRACAnalysis®, either prospectively or retrospectively. A statistically significant improvement in IDFS and OS was demonstrated in patients in the Lynparza arm compared with the placebo arm. Efficacy data for OlympiA (FAS) are presented in Table 22 and Figures 6 and 7. Table 22 Efficacy Results – OlympiA Lynparza tablets (N=921) Placebo (N=915) Invasive Disease Free Survival (IDFS) Data from the pre-specified interim analysis (86% of the number of events for the planned final analysis). Number of events (%) 106 (12) 178 (20) Hazard ratio (95% CI) Based on the stratified Cox's Proportional Hazards Model. 0.58 (0.46, 0.74) p‑value (2‑sided) p-value from a stratified log-rank test. Compared with the allocated alpha of 0.005 for IDFS and 0.015 for OS. < 0.0001 3-year event-free rate, % (95% CI) Percentage are calculated using Kaplan-Meier estimates. 86 (82.8, 88.4) 77 (73.7, 80.1) Overall Survival Data from the pre-specified second interim analysis of OS (at ~330 IDFS events). Number of events (%) 75 (8) 109 (12) Hazard ratio (95% CI) 0.68 (0.50, 0.91) p‑value (2-sided) 0.0091 3-year event-free rate, % (95% CI) 93 (90.8, 94.4) 89 (86.7, 91) CI = confidence interval. Figure 6 Kaplan-Meier Curves of IDFS – OlympiA Figure 7 Kaplan-Meier Curves of OS – OlympiA figure-6 figure-7 14.5 Treatment of Germline BRCA -mutated HER2-negative Metastatic Breast Cancer The efficacy of Lynparza was evaluated in OlympiAD (NCT02000622), an open-label randomized (2:1) study in patients with g BRCA m HER2-negative metastatic breast cancer. Patients were required to have received treatment with an anthracycline (unless contraindicated) and a taxane, in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor-positive disease must have progressed on at least 1 endocrine therapy (adjuvant or metastatic), or have disease that the treating healthcare provider believed to be inappropriate for endocrine therapy. Patients with prior platinum therapy were required to have no evidence of disease progress during platinum treatment. No prior treatment with a PARP inhibitor was permitted. Patients were randomized to Lynparza tablets 300 mg orally twice daily or healthcare provider’s choice of chemotherapy (capecitabine, eribulin, or vinorelbine, at standard doses) until progression or unacceptable toxicity. Randomization was stratified by prior use of chemotherapy for metastatic disease (yes vs no), hormone receptor status (hormone receptor positive vs triple negative), and previous use of platinum-based chemotherapy (yes vs no). The major efficacy outcome measure was PFS assessed by blinded independent central review (BICR) using RECIST version 1.1. A total of 302 patients were randomized, 205 to Lynparza and 97 to chemotherapy. Among the 205 patients treated with Lynparza, the median age was 44 years (range: 22 to 76), 65% were White, 4% were males and all the patients had an ECOG PS of 0 or 1. Approximately 50% of patients had triple-negative tumors and 50% had estrogen receptor and/or progesterone receptor positive tumors and the proportions were balanced across treatment arms. Patients in each treatment arm had received a median of 1 prior chemotherapy regimen for metastatic disease; approximately 30% had not received a prior chemotherapy regimen for metastatic breast cancer. Twenty-one percent of patients in the Lynparza arm and 14% in the chemotherapy arm had received platinum therapy for metastatic disease. Seven percent of patients in each treatment arm had received platinum therapy for localized disease. Of the 302 patients randomized onto OlympiAD, 299 were tested with the BRACAnalysis CDx ® and 297 were confirmed to have deleterious or suspected deleterious g BRCA m status; 202 were randomized to the Lynparza arm and 95 to the healthcare provider’s choice of chemotherapy arm. A statistically significant improvement in PFS was demonstrated for the Lynparza arm compared to the chemotherapy arm. Efficacy data for OlympiAD are displayed in Table 23 and Figure 8. Consistent results were observed across patient subgroups defined by study stratification factors. An exploratory analysis of investigator-assessed PFS was consistent with the BICR-assessed PFS results. Table 23 Efficacy Results - OlympiAD (BICR-assessed) Lynparza tablets (n=205) Chemotherapy (n=97) Progression-Free Survival Number of events (%) 163 (80%) 71 (73%) Median, months 7.0 4.2 Hazard ratio (95% CI) Hazard ratio is derived from a stratified log-rank test, stratified by ER, PgR negative versus ER and or PgR positive and prior chemotherapy (yes versus no). 0.58 (0.43, 0.80) p-value For PFS, p-value (2-sided) was compared to 0.05. 0.0009 Patients with Measurable Disease n=167 n=66 Objective Response Rate (95% CI) Response based on confirmed responses. The confirmed complete response rate was 7.8% for Lynparza compared to 1.5% for chemotherapy arm. 52% (44, 60) 23% (13, 35) Overall Survival Number of events (%) 130 (63%) 62 (64%) Median, months 19.3 17.1 Hazard ratio (95% CI) 0.90 (0.66, 1.23) Figure 8 Kaplan-Meier Curves of Progression-Free Survival - OlympiAD figure-8 14.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma The efficacy of Lynparza was evaluated in POLO (NCT02184195), a randomized (3:2), double-blind placebo-controlled, multi-center trial. Patients were required to have metastatic pancreatic adenocarcinoma with a deleterious or suspected deleterious germline BRCA mutation (g BRCA m) and absence of disease progression after receipt of first-line platinum-based chemotherapy for at least 16 weeks. Patients were randomized to receive Lynparza tablets 300 mg orally twice daily or placebo until disease progression or unacceptable toxicity. The major efficacy outcome measure was PFS by BICR using RECIST, version 1.1 modified to assess patients with clinical complete response at entry who were assessed as having no evidence of disease unless they had progressed based on the appearance of new lesions. Additional efficacy outcome measures were OS and ORR. A total of 154 patients were randomized, 92 to Lynparza and 62 to placebo. The median age was 57 years (range 36 to 84); 54% were male; 92% were White, 4% were Asian, and 3% were Black; baseline ECOG PS was 0 (67%) or 1 (31%). The median time from initiation of first-line platinum-based chemotherapy to randomization was 5.8 months (range 3.4 to 33.4 months). Seventy-five percent (75%) of patients received FOLFIRINOX with a median of 9 cycles (range 4-61), 8% received FOLFOX or XELOX, 4% received GEMOX, and 3% received gemcitabine plus cisplatin; 49% achieved a complete or partial response to platinum-based chemotherapy. All patients had a deleterious or suspected deleterious germline BRCA -mutation as detected by the Myriad BRAC Analysis ® or BRACAnalysis CDx ® at a central laboratory only (n=106), local BRCA test only (n=4), or both local and central testing (n=44). Among the 150 patients with central test results, 30% had a mutation in BRCA1 ; 69% had a mutation in BRCA2 ; and 1 patient (1%) had mutations in both BRCA1 and BRCA2 . POLO demonstrated a statistically significant improvement in BICR-assessed PFS in patients randomized to Lynparza as compared with placebo. The final analysis of OS did not reach statistical significance. Efficacy results of POLO are provided in Table 24 and Figure 9. Table 24 Efficacy Results - POLO (BICR-assessed) Lynparza tablets (n=92) Placebo (n=62) Progression-Free Survival Number of events (%) Number of events: Progression - Lynparza 55, placebo 44; death before BICR-documented progression - Lynparza 5, placebo 0. 60 (65) 44 (71) Median, months (95% CI) 7.4 (4.1, 11.0) 3.8 (3.5, 4.9) Hazard ratio Hazard ratio, 95% CI, and p-value calculated from a log-rank test. A hazard ratio <1 favors Lynparza. (95% CI) 0.53 (0.35, 0.81) p-value 0.0035 Overall Survival Number of events (%) 61 (66) 47 (76) Median, months (95% CI) 19.0 (15.3, 26.3) 19.2 (14.3, 26.1) Hazard ratio† (95% CI) 0.83 (0.56, 1.22) p-value 0.3487 Patients with Measurable Disease n=78 n=52 Objective Response Rate (95% CI) 23% (14, 34) 12% (4, 23) Complete response (%) 2 (2.6) 0 Partial response (%) 16 (21) 6 (12) Duration of Response (DOR) Median time in months (95% CI) 25 (15, NC) 4 (2, NC) NC Not calculable. Figure 9 Kaplan-Meier Curves of BICR-Assessed Progression-Free Survival – POLO figure-9 14.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer The efficacy of Lynparza was evaluated in PROfound (NCT02987543), randomized, open-label, multi-center trial that evaluated the efficacy of Lynparza 300 mg twice daily versus a comparator arm of investigator’s choice of enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (mCRPC). All patients received a GnRH analog or had prior bilateral orchiectomy. Patients needed to have progressed on prior enzalutamide or abiraterone for the treatment of metastatic prostate cancer and/or CRPC and have a tumor mutation in one of 15 genes involved in the homologous recombination repair (HRR) pathway. Patients were divided into two cohorts based on HRR gene mutation status. Patients with mutations in either BRCA1 , BRCA2 , or ATM were randomized in Cohort A; patients with mutations among 12 other genes involved in the HRR pathway ( BARD1 , BRIP1 , CDK12 , CHEK1 , CHEK2 , FANCL , PALB2 , PPP2R2A , RAD51B , RAD51C , RAD51D , or RAD54L ) were randomized in Cohort B; patients with co-mutations ( BRCA1 , BRCA2 , or ATM plus a Cohort B gene) were assigned to Cohort A. Although patients with PPP2R2A gene mutations were enrolled in the trial, Lynparza is not indicated for the treatment of patients with this gene mutation due to unfavorable risk-benefit. Patients were randomized (2:1), 256 to Lynparza arm and 131 to enzalutamide or abiraterone acetate arm; in Cohort A there were 245 (162 Lynparza arm and 83 in enzalutamide or abiraterone acetate arm) and in Cohort B there were 142 patients (94 in Lynparza arm and 48 in enzalutamide or abiraterone acetate arm). Randomization was stratified by prior receipt of taxane chemotherapy and presence of measurable disease by RECIST 1.1. Treatment was continued until objective radiological disease progression determined by BICR. Upon radiological progression confirmed by BICR, patients randomized to enzalutamide or abiraterone acetate were given the option to switch to Lynparza. Patients with HRR gene mutations were identified by tissue-based testing using the Foundation Medicine FoundationOne ® clinical trial HRR assay performed at a central laboratory. Determination of deleterious or suspected deleterious somatic or germline HRR mutation status in line with the FDA-approved mutation classification and testing criteria for the Foundation Medicine F1CDx tissue-based assay and assessment of the germline- BRCA status using the Myriad BRACAnalysis CDx blood-based assay was performed retrospectively. Representation of individual gene mutations by cohort is provided in Table 25. No patients were enrolled who had mutations in two of the 15 pre-specified HRR genes: FANCL and RAD51C . Table 25 Frequency of Patients with HRR Mutations Enrolled in PROfound HRR Mutation Cohort A N=245 n (%) Cohort B Three patients with single BRCA2 or ATM gene mutations and 1 patient with co-occurring BRCA2+CDK12 gene mutations were incorrectly assigned to Cohort B. N=142 n (%) Single mutation 224 (91) 135 (95) BRCA2 127 (52) 1 (<1) ATM 84 (34) 2 (1) BRCA1 13 (5) 0 CDK12 0 89 (63) CHEK2 0 12 (8) PPP2R2A Lynparza is not indicated for patients with PPP2R2A mutations. 0 10 (7) RAD51B 0 5 (4) RAD54L 0 5 (4) PALB2 0 4 (3) BRIP1 0 3 (2) CHEK1 0 2 (1) BARD1 0 1 (<1) RAD51D 0 1 (<1) Co-occurring mutation Patients with co-occurring mutations (BRCA1, BRCA2, or ATM plus a Cohort B gene) were assigned to Cohort A. 21 (9) 7 (5) In Cohort A+B, the median age was 69 years (range: 47 to 91 years) in both arms; 69% were White, 29% were Asian, and 1% were Black. The ECOG performance score was 0 or 1 in most patients (95%) in both arms. In patients treated with Lynparza, the proportion of patients with RECIST 1.1 measurable disease at baseline was 58%, including 17% with lung and 10% with liver metastases, respectively. At randomization, 66% of patients had received prior taxane chemotherapy, 40% had received enzalutamide, 38% had received abiraterone acetate, and 20% had received both enzalutamide and abiraterone acetate. Patient characteristics were well-balanced between arms. The major efficacy outcome of the study was radiological progression-free survival (rPFS) (Cohort A) as determined by BICR using RECIST version 1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) (bone) criteria. Additional efficacy outcomes included confirmed objective response rate (ORR) (Cohort A), rPFS (combined Cohorts A+B) as assessed by BICR, and overall survival (OS) (Cohort A). PROfound demonstrated a statistically significant improvement in BICR-assessed rPFS for Lynparza compared to investigator’s choice of enzalutamide or abiraterone acetate in Cohort A and Cohort A+B. In an exploratory analysis for patients in Cohort B, the median rPFS was 4.8 months for Lynparza vs 3.3 months for comparator with a HR of 0.88 (95% CI 0.58, 1.36). The major efficacy outcome was supported by a statistically significant improvement in ORR by BICR for patients with measurable disease at baseline in Cohort A. In Cohort B, ORR by BICR was 3.7% (95% CI 0.5, 12.7) in Lynparza treated patients and 8.3% (95% CI 1.0, 27.0) in patients treated with enzalutamide or abiraterone acetate. The final analysis of overall survival (OS) demonstrated a statistically significant improvement in OS in patients randomized to Lynparza compared to patients in the enzalutamide or abiraterone acetate arm in Cohort A. Efficacy results of PROfound are provided in Tables 26 and 27 and Figures 10 and 11. Table 26 Efficacy Results - PROfound (BICR-assessed) Cohort A Cohort A+B Although 10 patients with PPP2R2A mutation were included in all analyses of Cohort A+B, Lynparza is not indicated for this population due to unfavorable risk-benefit. Lynparza tablets (n=162) Enzalutamide or Abiraterone acetate (n=83) Lynparza tablets (n=256) Enzalutamide or Abiraterone acetate (n=131) Radiological Progression-Free Survival (rPFS) Number of events (%) 106 (65) 68 (82) 180 (70) 99 (76) Median (95% CI), in months 7.4 (6.2, 9.3) 3.6 (1.9, 3.7) 5.8 (5.5, 7.4) 3.5 (2.2, 3.7) Hazard ratio (95% CI) The HR and CI were calculated using a Cox proportional hazards model adjusted for prior taxane use and measurable disease. An HR <1 favors Lynparza 300 mg taken orally twice daily. 0.34 (0.25, 0.47) 0.49 (0.38, 0.63) p-value The analysis was performed using the log-rank test stratified by prior taxane use and measurable disease. <0.0001 <0.0001 Confirmed ORR Patients with measurable disease at baseline n=84 n=43 - - ORR, n (%) 28 (33) 1 (2) - - (95% CI) (23, 45) (0, 12) - - p-value <0.0001 - Overall Survival n=162 n=83 - - Number of events (%) 91 (56) 57 (69) - - Median (95% CI), in months 19.1 (17.4, 23.4) 14.7 (11.9, 18.8) - - Hazard ratio (95% CI) 0.69 (0.50, 0.97) - p-value 0.0175 - CI Confidence interval Figure 10 Kaplan-Meier Curves of BICR-Assessed rPFS – PROfound – Cohort A Consistent results were observed in exploratory analyses of rPFS for patients who received or did not receive prior taxane therapy and for those with germline- BRCA mutations identified using the Myriad BRACAnalysis CDx assay compared with those with BRCA mutations identified using the Foundation Medicine F1CDx assay. Figure 11 Kaplan-Meier Curves of Overall Survival – PROfound – Cohort A Response data by HRR mutations for patients in the Lynparza arm are presented in Table 27. In the comparator arm of Cohorts A and B, a total of three patients achieved a partial response, including one patient with an ATM mutation alone and 2 patients with co-occurring mutations (one with PALB2 + PPP2R2A and one with CDK12 + PALB2 ). Table 27 Response Rate and Duration of Response by HRR Mutation in Patients with Measurable Disease at Baseline on the Lynparza Arm – PROfound (BICR-assessed) HRR mutation No patients with FANCL or RAD51C enrolled. Three patients with PPP2R2A mutations had measurable disease, however, Lynparza is not indicated for patients with PPP2R2A mutation. Patients (N=138) Confirmed ORR In patients with a single BRCA2 mutation the median duration of response in the Lynparza arm (n=24) was 5.6 months (95% C.I: 5.5, 9.2). In the 3 responders with a single ATM mutation in the Lynparza arm, the duration of response ranged from 5.8+ to 9.0 months. In the 2 responders with a single CDK12 mutation in the Lynparza arm, the duration of response was 3.7 and 7.2 months. + denotes ongoing response. n (%) 95% CI Single mutation BRCA2 43 24 (56) (40, 71) ATM 30 3 (10) (2, 27) CDK12 34 2 (6) (1, 20) BRCA1 6 SD, PD (4), NE NA CHEK2 4 SD (2), PD (2) NA BRIP1 2 SD, PD NA PALB2 2 SD, PD NA CHEK1 1 PD NA RAD51B 1 SD NA RAD51D 1 PD NA RAD54L 1 SD NA Co-occurring mutations BRCA2/CDK12 2 PR, SD NA BRCA2/ATM 2 SD, SD NA BRCA2/BARD1 1 PD NA BRCA2/CHEK2 1 SD NA CDK12/CHEK1 1 SD NA CDK12/PALB2 1 PD NA BRCA2/CDK12/CHEK2 1 PD NA BRCA2/CHEK2/RAD51D 1 SD NA PR Partial response; SD Stable disease; PD Progressive disease; NE Not evaluable; NA Not applicable due to small numbers or lack of response. figure_10 Figure 11 14.8 Treatment of BRCA-mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone The efficacy of Lynparza in the treatment of patients with mCRPC was investigated in PROpel (NCT03732820), a randomized, double-blind, placebo-controlled, multi-center study that compared the efficacy of Lynparza in combination with abiraterone with placebo plus abiraterone for patients with mCRPC. Patients (n=796) were randomized (1:1) to receive Lynparza tablets 300 mg orally twice daily in combination with abiraterone 1000 mg daily (n=399) compared with placebo plus abiraterone (n=397). All patients received either prednisone or prednisolone 5 mg twice daily, and a GnRH analog or prior bilateral orchiectomy. Patients with prior treatment with abiraterone were excluded. Prior docetaxel for localized or metastatic hormone-sensitive prostate cancer (mHSPC) was allowed. Randomization was stratified by metastases (bone only, visceral, or other) and docetaxel treatment at mHSPC stage (yes or no). Lynparza treatment was continued until objective radiological disease progression determined by investigator or unacceptable toxicity. BRCA gene mutation ( BRCA m) status was assessed after randomization and before primary analysis by both NGS-based tumor tissue and ctDNA tests. BRCA m classification criteria in line with the FDA approved assays were used to determine the deleterious and suspected deleterious somatic or germline mutation status of patients. The major efficacy outcome measure was investigator-assessed rPFS evaluated according to RECIST, version 1.1 and Prostate Cancer Working Group (PCWG3) (bone) criteria. Overall survival (OS) was an additional efficacy outcome measure. Of the 796 patients tested, 85 (11%) had BRCA m determined by either a positive ctDNA test (9%) or a tumor tissue test (6%). Among these 85 patients, the median age was 68 years (range 43 to 85), and 67% were 65 years or older; 72% were White, 22% Asian, and 2% Black or African American; 66% had ECOG performance status (PS) 0 and 34% had ECOG PS 1; 25% had prior docetaxel treatment for mHSPC; 53% had bone-only metastases, 15% had visceral metastases, and 32% had other metastases. A statistically significant improvement in rPFS for Lynparza/abiraterone compared to placebo/abiraterone was observed in the intention to treat (ITT) population. In an exploratory analysis in the subgroup of 711 patients without an identified BRCA m, the rPFS hazard ratio was 0.77 (95% CI: 0.63, 0.96) and the OS hazard ratio was 0.92 (95% CI: 0.74, 1.14), indicating that the improvement in the ITT population was primarily attributed to the results seen in the subgroup of patients with BRCA m. Results of an exploratory analysis in the subgroup of 85 patients on PROpel with BRCA m are summarized in Table 28 and Figure 12 and 13. Results from the BICR assessment were consistent with the investigator-assessed rPFS results. Table 28 Efficacy Results – PROpel (Patients with BRCAm) Lynparza/abiraterone N = 47 Placebo/abiraterone N = 38 Radiological Progression-Free Survival (rPFS) Investigator-assessed. Events, n (%) 14 (30) 28 (74) Median (95% CI), months NR (NR, NR) 8 (6, 15) Hazard ratio (95% CI) Calculated using an unstratified univariable Cox proportional hazards model. 0.24 (0.12, 0.45) Overall Survival (OS) Events, n (%) 13 (28) 25 (66) Median (95% CI), months NR (NR, NR) 23 (18, 34) Hazard ratio (95% CI) 0.30 (0.15, 0.59) NR: Not reached. Figure 12 Kaplan-Meier Curves of rPFS – PROpel (Patients with BRCA m, Investigator Assessment) Figure 13 Kaplan-Meier Curves of OS – PROpel (Patients with BRCA m) figure-12 figure-13"],"pharmacokinetics":["12.3 Pharmacokinetics The area under the curve (AUC) of olaparib increases approximately proportionally following administration of single doses of 25 mg to 450 mg (0.08 to 1.5 times the recommended dose) and maximal concentrations (C max ) increased slightly less than proportionally for the same dose range. Olaparib showed time-dependent pharmacokinetics and an AUC mean accumulation ratio of 1.8 is observed at steady state following a dose of 300 mg twice daily. The mean (CV%) olaparib C max is 5.4 μg/mL (32%) and AUC is 39.2 μg*h/mL (44%) following a single 300 mg dose. The mean steady state olaparib C max and AUC is 7.6 μg/mL (35%) and 49.2 μg*h/mL (44%), following a dose of 300 mg twice daily. Absorption Following oral administration of olaparib, the median time to peak plasma concentration is 1.5 hours. Effect of Food Co-administration of a high fat and high calorie meal (800-1000 kcal, 50% of the calorie content made up from fat) with olaparib slowed the rate (t max delayed by 2.5 hours) of absorption, but did not significantly alter the extent of olaparib absorption (mean AUC increased by approximately 8%). Distribution The mean (± standard deviation) apparent volume of distribution of olaparib is 158 ± 136 L following a single 300 mg dose of Lynparza. The protein binding of olaparib is approximately 82% in vitro. Elimination The mean (± standard deviation) terminal plasma half-life of olaparib is 14.9 ± 8.2 hours and the apparent plasma clearance is 7.4 ± 3.9 L/h following a single 300 mg dose of Lynparza. Metabolism Olaparib is metabolized by cytochrome P450 (CYP) 3A in vitro. Following an oral dose of radiolabeled olaparib to female patients, unchanged olaparib accounted for 70% of the circulating radioactivity in plasma. It was extensively metabolized with unchanged drug accounting for 15% and 6% of radioactivity in urine and feces, respectively. The majority of the metabolism is attributable to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation. Excretion Following a single dose of radiolabeled olaparib, 86% of the dosed radioactivity was recovered within a 7-day collection period, 44% via the urine and 42% via the feces. The majority of the material was excreted as metabolites. Specific Populations Patients with Renal Impairment In a renal impairment trial, the mean AUC increased by 24% and C max by 15%, when olaparib was dosed in patients with mild renal impairment (CLcr=51-80 mL/min defined by the Cockcroft-Gault equation; n=13) and by 44% and 26%, respectively, when olaparib was dosed in patients with moderate renal impairment (CLcr=31-50 mL/min; n=13), compared to those with normal renal function (CLcr ≥81 mL/min; n=12). There was no evidence of a relationship between the extent of plasma protein binding of olaparib and creatinine clearance. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min). Patients with Hepatic Impairment In a hepatic impairment trial, the mean AUC increased by 15% and the mean C max increased by 13% when olaparib was dosed in patients with mild hepatic impairment (Child-Pugh classification A; n=10) and the mean AUC increased by 8% and the mean C max decreased by 13% when olaparib was dosed in patients with moderate hepatic impairment (Child-Pugh classification B; n=8), compared to patients with normal hepatic function (n=13). Hepatic impairment has no effect on the protein binding of olaparib and, therefore, total plasma exposure was representative of free drug. There are no data in patients with severe hepatic impairment (Child-Pugh classification C). Drug Interaction Studies Clinical Studies CYP3A Inhibitors: Concomitant use of itraconazole (strong CYP3A inhibitor) increased olaparib C max by 42% and AUC by 170%. Concomitant use of fluconazole (moderate CYP3A inhibitor) is predicted to increase olaparib C max by 14% and AUC by 121%. CYP3A Inducers : Concomitant use of rifampicin (strong CYP3A inducer) decreased olaparib C max by 71% and AUC by 87%. Concomitant use of efavirenz (moderate CYP3A inducer) is predicted to decrease olaparib C max by 31% and AUC by 60%. In vitro Studies CYP Enzymes : Olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Olaparib is predicted to be a weak CYP3A inhibitor in humans. UGT Enzymes : Olaparib is an inhibitor of UGT1A1. Transporters : Olaparib is an inhibitor of BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1, and MATE2K. Olaparib is a substrate and inhibitor of the efflux transporter P-gp. The potential for olaparib to induce P-gp has not been evaluated."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere in the labeling: • Myelodysplastic Syndrome/Acute Myeloid Leukemia [see Warnings and Precautions (5.1) ] • Pneumonitis [see Warnings and Precautions (5.2) ] • Venous Thromboembolism [see Warnings and Precautions (5.3) ] • Hepatotoxicity, Including Drug-Induced Liver Injury [see Warnings and Precautions (5.4) ] Most common adverse reactions (≥10%): • as a single agent were nausea, fatigue (including asthenia), anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, and thrombocytopenia. (6.1) • in combination with bevacizumab were nausea, fatigue (including asthenia), anemia, lymphopenia, vomiting, diarrhea, neutropenia, leukopenia, urinary tract infection, and headache. ( 6.1 ) • in combination with abiraterone and prednisone or prednisolone were anemia, fatigue, nausea, diarrhea, decreased appetite, lymphopenia, dizziness, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Unless otherwise specified, the data described in the WARNINGS AND PRECAUTIONS reflect exposure to Lynparza as a single agent or as part of a combination regimen (SOLO-1, SOLO-2, PAOLA-1, OlympiA, OlympiAD, POLO, PROfound, and PROpel) in 2851 patients that were pooled to conduct safety analyses. Additional data reflect exposure to Lynparza as a single agent in 2901 patients; 2135 patients with exposure to 300 mg twice daily tablet dose including five controlled, randomized, trials (SOLO-1, SOLO-2, OlympiAD, POLO, and PROfound) and to 400 mg twice daily capsule dose in 766 patients in other trials that were pooled to conduct safety analyses. In this pooled single agent safety population, 56% of patients were exposed for 6 months or longer and 28% were exposed for greater than one year in the Lynparza group. In this pooled single agent safety population, the most common adverse reactions in ≥10% of patients were nausea (60%), fatigue (55%), anemia (36%), vomiting (32%), diarrhea (24%), decreased appetite (22%), headache (16%), dysgeusia (15%), cough (15%), neutropenia (14%), dyspnea (14%), dizziness (12%), dyspepsia (12%), leukopenia (11%), and thrombocytopenia (10%). First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer SOLO-1 The safety of Lynparza for the maintenance treatment of patients with BRCA-mutated advanced ovarian cancer following first-line treatment with platinum-based chemotherapy was investigated in SOLO- 1 [see Clinical Studies (14.1) ] . Patients received Lynparza tablets 300 mg orally twice daily (n=260) or placebo (n=130) until disease progression or unacceptable toxicity. The median duration of study treatment was 25 months for patients who received Lynparza and 14 months for patients who received placebo. Among patients who received Lynparza, dose interruptions due to an adverse reaction of any grade occurred in 52% and dose reductions due to an adverse reaction occurred in 28%. The most frequent adverse reactions leading to dose interruption or reduction of Lynparza were anemia (23%), nausea (14%), and vomiting (10%). Discontinuation due to adverse reactions occurred in 12% of patients receiving Lynparza. The most frequent adverse reactions that led to discontinuation of Lynparza were fatigue (3.1%), anemia (2.3%), and nausea (2.3%). Tables 2 and 3 summarize adverse reactions and laboratory abnormalities in SOLO-1. Table 2 Adverse Reactions Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. in SOLO-1 (≥10% of Patients Who Received Lynparza) Adverse Reaction Lynparza tablets n=260 Placebo n=130 All Grades (%) Grades 3 – 4 (%) All Grades (%) Grades 3 – 4 (%) Gastrointestinal Disorders Nausea 77 1 38 0 Abdominal pain Includes abdominal pain, abdominal pain lower, abdominal pain upper, abdominal distension, abdominal discomfort, and abdominal tenderness. 45 2 35 1 Vomiting 40 0 15 1 Diarrhea Includes colitis, diarrhea, and gastroenteritis. 37 3 26 0 Constipation 28 0 19 0 Dyspepsia 17 0 12 0 Stomatitis Includes stomatitis, aphthous ulcer, and mouth ulceration. 11 0 2 0 General Disorders and Administration Site Conditions Fatigue Includes asthenia, fatigue, lethargy, and malaise. 67 4 42 2 Blood and Lymphatic System Disorders Anemia 38 21 9 2 Neutropenia Includes neutropenia and febrile neutropenia. 17 6 7 3 Leukopenia Includes leukopenia and white blood cell count decreased. 13 3 8 0 Thrombocytopenia Includes platelet count decreased and thrombocytopenia. 11 1 4 2 Infections and Infestations Upper respiratory tract infection/ influenza/nasopharyngitis/bronchitis 28 0 23 0 UTI Includes urosepsis, urinary tract infection, urinary tract pain, and pyuria. 13 1 7 0 Nervous System Disorders Dysgeusia 26 0 4 0 Dizziness 20 0 15 1 Metabolism and Nutrition Disorders Decreased appetite 20 0 10 0 Respiratory, Thoracic and Mediastinal Disorders Dyspnea Includes dyspnea and dyspnea exertional. 15 0 6 0 Clinically relevant adverse reactions that occurred in <10% of patients receiving Lynparza were increased blood creatinine (8%), lymphopenia (6%), VTE (3%), hypersensitivity (2%), MDS/AML (1.9%), pneumonitis (1.9%), dermatitis (1%), and increased mean cell volume (0.4%). Table 3 Laboratory Abnormalities Reported in ≥25% of Patients in SOLO-1 Laboratory Parameter Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Lynparza tablets n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. =260 Placebo n =130 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Decrease in hemoglobin 87 19 63 2 Increase in mean corpuscular volume 87 - 43 - Decrease in leukocytes 70 7 52 1 Decrease in lymphocytes 67 14 29 5 Decrease in absolute neutrophil count 51 9 38 6 Decrease in platelets 35 1 20 2 Increase in serum creatinine 34 0 18 0 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab PAOLA-1 The safety of Lynparza in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer following first-line treatment containing platinum-based chemotherapy and bevacizumab was investigated in PAOLA-1 [see Clinical Studies (14.2) ] . This study was a placebo-controlled, double-blind study in which 802 patients received either Lynparza 300 mg BID in combination with bevacizumab (n=535) or placebo in combination with bevacizumab (n=267) until disease progression or unacceptable toxicity. The median duration of treatment with Lynparza was 17.3 months and 11 months for bevacizumab post-randomization on the Lynparza/bevacizumab arm. Fatal adverse reactions occurred in 1 patient due to concurrent pneumonia and aplastic anemia. Serious adverse reactions occurred in 31% of patients who received Lynparza/bevacizumab. Serious adverse reactions in >5% of patients included hypertension (19%) and anemia (17%). Dose interruptions due to an adverse reaction of any grade occurred in 54% of patients receiving Lynparza/bevacizumab and dose reductions due to an adverse reaction occurred in 41% of patients who received Lynparza/bevacizumab. The most frequent adverse reactions leading to dose interruption in the Lynparza/bevacizumab arm were anemia (21%), nausea (7%), vomiting (3%), and fatigue (3%), and the most frequent adverse reactions leading to reduction in the Lynparza/bevacizumab arm were anemia (19%), nausea (7%), and fatigue (4%). Discontinuation due to adverse reactions occurred in 20% of patients receiving Lynparza/bevacizumab. Specific adverse reactions that most frequently led to discontinuation in patients treated with Lynparza/bevacizumab were anemia (4%) and nausea (3%). The most common adverse reactions (≥10%) for patients receiving Lynparza/bevacizumab irrespective of the frequency compared with the placebo/bevacizumab arm were nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%), diarrhea (18%), neutropenia (18%), leukopenia (18%), urinary tract infection (15%), and headache (14%). Tables 4 and 5 summarize adverse reactions and laboratory abnormalities in PAOLA-1, respectively. Table 4 Adverse Reactions Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. Occurring in ≥10% of Patients Treated with Lynparza/bevacizumab in PAOLA-1 and at ≥5% Frequency Compared to the Placebo/bevacizumab Arm Adverse Reactions Lynparza/bevacizumab n=535 Placebo/bevacizumab n=267 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) General Disorders and Administration Site Conditions Fatigue (including asthenia) Includes asthenia and fatigue. 53 5 32 1.5 Gastrointestinal Disorders Nausea 53 2.4 22 0.7 Vomiting 22 1.7 11 1.9 Blood and Lymphatic Disorders Anemia Includes anemia, anemia macrocytic, erythropenia, haematocrit decreased, haemoglobin decreased, normochromic anemia, normochromic normocytic anemia, normocytic anemia, and red blood cell count decreased. 41 17 10 0.4 Lymphopenia Includes B-lymphocyte count decreased, lymphocyte count decreased, lymphopenia, and T-lymphocyte count decreased. 24 7 9 1.1 Leukopenia Includes leukopenia and white blood cell count decreased. 18 1.9 10 1.5 Clinically relevant adverse reactions that occurred in <10% of patients receiving Lynparza/bevacizumab were dysgeusia (8%), dyspnea (8%), stomatitis (5%), dyspepsia (4.3%), erythema (3%), dizziness (2.6%), hypersensitivity (1.7%), pneumonitis (0.9%), and MDS/AML (0.7%). Venous thromboembolism occurred more commonly in patients receiving Lynparza/bevacizumab (5%) than in those receiving placebo/bevacizumab (1.9%). Table 5 Laboratory Abnormalities Reported in ≥25% of Patients in PAOLA-1 Reported within 30 days of the last dose. Laboratory Parameter Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Lynparza/bevacizumab n =535 Placebo/bevacizumab n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. =267 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Decrease in hemoglobin 79 13 55 0.4 Decrease in lymphocytes 63 10 42 3 Increase in serum creatinine 61 0.4 36 0.4 Decrease in leukocytes 59 3.4 45 2.2 Decrease in absolute neutrophil count 35 7 30 3.7 Decrease in platelets 35 2.4 28 0.4 Maintenance Treatment of BRCA -mutated Recurrent Ovarian Cancer SOLO-2 The safety of Lynparza for the maintenance treatment of patients with platinum sensitive g BRCA m ovarian cancer was investigated in SOLO-2 [see Clinical Studies (14.3) ] . Patients received Lynparza tablets 300 mg orally twice daily (n=195) or placebo (n=99) until disease progression or unacceptable toxicity. The median duration of study treatment was 19.4 months for patients who received Lynparza and 5.6 months for patients who received placebo. Among patients who received Lynparza, dose interruptions due to an adverse reaction of any grade occurred in 45% and dose reductions due to an adverse reaction occurred in 27%. The most frequent adverse reactions leading to dose interruption or reduction of Lynparza were anemia (22%), neutropenia (9%), and fatigue/asthenia (8%). Discontinuation due to an adverse reaction occurred in 11% of patients receiving Lynparza. Tables 6 and 7 summarize adverse reactions and laboratory abnormalities in SOLO-2. Table 6 Adverse Reactions Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0. in SOLO-2 (≥20% of Patients Who Received Lynparza) Adverse Reaction Lynparza tablets n=195 Placebo n=99 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Gastrointestinal Disorders Nausea 76 3 33 0 Vomiting 37 3 19 1 Diarrhea 33 2 22 0 Stomatitis Represents grouped term consisting of abscess oral, aphthous ulcer, gingival abscess, gingival disorder, gingival pain, gingivitis, mouth ulceration, mucosal infection, mucosal inflammation, oral candidiasis, oral discomfort, oral herpes, oral infection, oral mucosal erythema, oral pain, oropharyngeal discomfort, and oropharyngeal pain. 20 1 16 0 General Disorders and Administration Site Conditions Fatigue including asthenia 66 4 39 2 Blood and Lymphatic Disorders Anemia Represents grouped term consisting of anemia, hematocrit decreased, hemoglobin decreased, iron deficiency, mean cell volume increased, and red blood cell count decreased. 44 20 9 2 Infections and Infestations Nasopharyngitis/URI/sinusitis/ rhinitis/influenza 36 0 29 0 Musculoskeletal and Connective Tissue Disorders Arthralgia/myalgia 30 0 28 0 Nervous System Disorders Dysgeusia 27 0 7 0 Headache 26 1 14 0 Metabolism and Nutrition Disorders Decreased appetite 22 0 11 0 Clinically relevant adverse reactions that occurred in <20% of patients receiving Lynparza were neutropenia (19%), cough (18%), leukopenia (16%), hypomagnesemia (14%), thrombocytopenia (14%), dizziness (13%), dyspepsia (11%), increased creatinine (11%), MDS/AML (8%), edema (8%), rash (6%), VTE (5%), pneumonitis (1%), and lymphopenia (1%). Table 7 Laboratory Abnormalities Reported in ≥25% of Patients in SOLO-2 Laboratory Parameter Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Lynparza tablets n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. =195 Placebo n =99 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Increase in mean corpuscular volume Represents the proportion of subjects whose mean corpuscular volume was > upper limit of normal (ULN). 89 - 52 - Decrease in hemoglobin 83 17 69 0 Decrease in leukocytes 69 5 48 1 Decrease in lymphocytes 67 11 37 1 Decrease in absolute neutrophil count 51 7 34 3 Increase in serum creatinine 44 0 29 0 Decrease in platelets 42 2 22 1 Adjuvant Treatment of germline BRCA -mutated HER2-negative High Risk Early Breast Cancer OlympiA The safety of Lynparza as monotherapy for the adjuvant treatment of patients with gBRCA-mutated HER2-negative high risk early breast cancer was investigated in OlympiA [see Clinical Studies (14.4) ] . This study was a randomized, double-blind, multi-center study in which patients received either Lynparza tablets 300 mg orally twice daily (n=911) or placebo (n=904) for a total of 1 year, or until disease recurrence, or unacceptable toxicity. The median duration of treatment was 1 year in both arms. Dose interruptions due to an adverse reaction of any grade occurred in 31% of patients receiving Lynparza; dose reductions due to an adverse reaction occurred in 23% of patients receiving Lynparza. The most frequent adverse reactions leading to dose interruption of Lynparza were anemia (11%), neutropenia (6%), nausea (5%), leukopenia (3.5%), fatigue (3%), and vomiting (2.9%) and the most frequent adverse reactions leading to dose reduction of Lynparza were anemia (8%), nausea (4.7%), neutropenia (4.2%), fatigue (3.3%), leukopenia (1.8%), and vomiting (1.5%). Discontinuation due to adverse reactions occurred in 10% of patients receiving Lynparza. The adverse reactions that most frequently led to discontinuation of Lynparza were nausea (2%), anemia (1.8%), and fatigue (1.3%). Tables 8 and 9 summarize the adverse reactions and laboratory abnormalities, respectively, in patients in OlympiA. Table 8 Adverse Reactions Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03 in OlympiA (≥ 10% of Patients Who Received Lynparza) Adverse Reactions Lynparza tablets n=911 Placebo n=904 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Gastrointestinal Disorders Nausea 57 0.8 23 0 Vomiting 23 0.7 8 0 Diarrhea 18 0.3 14 0.3 Stomatitis Includes aphthous ulcer, mouth ulceration, and stomatitis. 10 0.1 4.5 0 General Disorders and Administration Site Conditions Fatigue (including asthenia) 42 1.8 28 0.7 Blood and Lymphatic Disorders Anemia Includes anemia, anemia macrocytic, erythropenia, hematocrit decreased, hemoglobin decreased, normochromic anemia, normochromic normocytic anemia, normocytic anemia, and red blood cell count decreased. 24 9 3.9 0.3 Leukopenia Includes leukopenia and white blood cell count decreased. 17 3 6 0.3 Neutropenia Includes agranulocytosis, febrile neutropenia, granulocyte count decreased, granulocytopenia, idiopathic neutropenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased. 16 5 7 0.8 Nervous System Disorders Headache 20 0.2 17 0.1 Dysgeusia Includes dysgeusia and taste disorder. 12 0 4.8 0 Dizziness 11 0.1 7 0.1 Metabolism and Nutrition Disorders Decreased appetite 13 0.2 6 0 Clinically relevant adverse reactions that occurred in <10% of patients receiving Lynparza were cough (9.2%), lymphopenia (7%), dyspepsia (6%), upper abdominal pain (4.9%), rash (4.9%), dyspnea (4.2%), thrombocytopenia (4.2%), increase in creatinine (2%), hypersensitivity (0.9%), pneumonitis (0.8%), VTE (0.5%), dermatitis (0.5%), increase in mean corpuscular volume (0.2%), and MDS/AML (0.2%). Table 9 Laboratory Abnormalities Reported in ≥25% of Patients in OlympiA Laboratory Parameter Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Lynparza tablets n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. = 911 Placebo n =904 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Decrease in lymphocytes 77 13 59 3.7 Increase in mean corpuscular volume Represents the proportion of subjects whose mean corpuscular volume was > ULN. 67 0 4.8 0 Decrease in hemoglobin 65 8 31 0.9 Decrease in leukocytes 64 5 42 0.7 Decrease in absolute neutrophil count 39 7 27 1.1 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer OlympiAD The safety of Lynparza was evaluated in g BRCA m patients with HER2-negative metastatic breast cancer who had previously received up to two lines of chemotherapy for the treatment of metastatic disease in OlympiAD [see Clinical Studies (14.5) ] . Patients received either Lynparza tablets 300 mg orally twice daily (n=205) or a chemotherapy (capecitabine, eribulin, or vinorelbine) of the healthcare provider’s choice (n=91) until disease progression or unacceptable toxicity. The median duration of study treatment was 8.2 months in patients who received Lynparza and 3.4 months in patients who received chemotherapy. Among patients who received Lynparza, dose interruptions due to an adverse reaction of any grade occurred in 35% and dose reductions due to an adverse reaction occurred in 25%. Discontinuation due to an adverse reaction occurred in 5% of patients receiving Lynparza. Tables 10 and 11 summarize the adverse reactions and laboratory abnormalities in OlympiAD. Table 10 Adverse Reactions Graded according to NCI CTCAE v4.0. in OlympiAD (≥20% of Patients Who Received Lynparza) Adverse Reaction Lynparza tablets n=205 Chemotherapy n=91 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Gastrointestinal Disorders Nausea 58 0 35 1 Vomiting 30 0 15 1 Diarrhea 21 1 22 0 Blood and Lymphatic Disorders Anemia Represents grouped terms consisting of anemia (anemia erythropenia, hematocrit decreased, hemoglobin decreased, and red blood cell count decreased). 40 16 26 4 Neutropenia Represents grouped terms consisting of neutropenia (febrile neutropenia, granulocyte count decreased, granulocytopenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased). 27 9 50 26 Leukopenia Represents grouped terms consisting of leukopenia (leukopenia and white blood cell count decreased). 25 5 31 13 General Disorders and Administration Site Conditions Fatigue (including asthenia) 37 4 36 1 Infections and Infestations Respiratory tract infection Represents grouped terms consisting of bronchitis, influenza, lower respiratory tract infection, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, upper respiratory tract infection, and upper respiratory tract infection bacterial. 27 1 22 0 Nervous System Disorders Headache 20 1 15 2 Clinically relevant adverse reactions that occurred in <20% of patients receiving Lynparza were cough (18%), decreased appetite (16%), thrombocytopenia (11%), dysgeusia (9%), lymphopenia (8%), dyspepsia (8%), dizziness (7%), stomatitis (7%), upper abdominal pain (7%), rash (5%), increase in serum creatinine (3%), dermatitis (1%), and VTE (1%). Table 11 Laboratory Abnormalities Reported in ≥25% of Patients in OlympiAD Laboratory Parameter Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Lynparza tablets n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. = 205 Chemotherapy n = 91 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Decrease in hemoglobin 82 17 66 3 Decrease in lymphocytes 73 21 63 3 Decrease in leukocytes 71 8 70 23 Increase in mean corpuscular volume Represents the proportion of subjects whose mean corpuscular volume was > ULN. 71 - 33 - Decrease in absolute neutrophil count 46 11 65 38 Decrease in platelets 33 3 28 0 First-line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma POLO The safety of Lynparza as maintenance treatment of germline BRCA -mutated metastatic pancreatic adenocarcinoma following first-line treatment with platinum-based chemotherapy was evaluated in POLO [see Clinical Studies (14.6) ] . Patients received Lynparza tablets 300 mg orally twice daily (n=90) or placebo (n=61) until disease progression or unacceptable toxicity. Among patients receiving Lynparza, 34% were exposed for 6 months or longer and 25% were exposed for greater than one year. Among patients who received Lynparza, dosage interruptions due to an adverse reaction of any grade occurred in 35% and dosage reductions due to an adverse reaction occurred in 17%. The most frequent adverse reactions leading to dosage interruption or reduction in patients who received Lynparza were anemia (11%), vomiting (5%), abdominal pain (4%), asthenia (3%), and fatigue (2%). Discontinuation due to adverse reactions occurred in 6% of patients receiving Lynparza. The most frequent adverse reaction that led to discontinuation of Lynparza was fatigue (2.2%). Tables 12 and 13 summarize the adverse reactions and laboratory abnormalities in patients in POLO. Table 12 Adverse Reactions Graded according to NCI CTCAE, version 4.0. in POLO (Occurring in ≥10% of Patients who Received Lynparza) Adverse Reaction Lynparza tablets (n=91) This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. Placebo (n=60) All Grades (%) Grades 3 – 4 (%) All Grades (%) Grades 3 – 4 (%) General Disorders and Administration Site Conditions Fatigue Includes asthenia and fatigue. 60 5 35 2 Gastrointestinal Disorders Nausea 45 0 23 2 Abdominal pain Includes abdominal pain, abdominal pain upper, and abdominal pain lower. 34 2 37 5 Diarrhea 29 0 15 0 Constipation 23 0 10 0 Vomiting 20 1 15 2 Stomatitis Includes stomatitis and mouth ulceration. 10 0 5 0 Blood and Lymphatic System Disorders Anemia 27 11 17 3 Thrombocytopenia Includes platelets count decreased and thrombocytopenia. 14 3 7 0 Neutropenia Includes neutropenia, febrile neutropenia, and neutrophil count decreased. 12 4 8 3 Metabolism and Nutrition Disorders Decreased appetite 25 3 7 0 Musculoskeletal and Connective Tissue Disorders Back pain 19 0 17 2 Arthralgia 15 1 10 0 Skin and Subcutaneous Tissue Disorder Rash Includes rash erythematous, rash macular, and rash maculo-papular. 15 0 5 0 Respiratory, Thoracic and Mediastinal Disorders Dyspnea Includes dyspnea and dyspnea exertional. 13 0 5 2 Infections and Infestations Nasopharyngitis 12 0 3 0 Nervous System Disorders Dysgeusia 11 0 5 0 Clinically relevant adverse reactions that occurred in <10% of patients receiving Lynparza were cough (9%), abdominal pain upper (7%), blood creatinine increased (7%), dizziness (7%), headache (7%), dyspepsia (5%), leukopenia (5%), VTE (3%), hypersensitivity (2%), and lymphopenia (2%), and pneumonitis (1.1%). Table 13 Laboratory Abnormalities Reported in ≥25% of Patients in POLO Laboratory Parameter Patients were allowed to enter POLO with hemoglobin ≥9 g/dL (CTCAE Grade 2) and other laboratory values of CTCAE Grade 1. Lynparza tablets n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. =91 Placebo n =60 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Increase in serum creatinine 99 2 85 0 Decrease in hemoglobin 86 11 65 0 Increase in mean corpuscular volume Represents the proportion of subjects whose mean corpuscular volume was > ULN. 71 - 30 - Decrease in lymphocytes 61 9 27 0 Decrease in platelets 56 2 39 0 Decrease in leukocytes 50 3 23 0 Decrease in absolute neutrophil count 25 3 10 0 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer PROfound The safety of Lynparza as monotherapy was evaluated in patients with mCRPC and HRR gene mutations who have progressed following prior treatment with enzalutamide or abiraterone in PROfound [see Clinical Studies (14.7) ] . This study was a randomized, open-label, multi-center study in which 386 patients received either Lynparza tablets 300 mg orally twice daily (n=256) or investigator’s choice of enzalutamide or abiraterone acetate (n=130) until disease progression or unacceptable toxicity. Among patients receiving Lynparza, 62% were exposed for 6 months or longer and 20% were exposed for greater than one year. Fatal adverse reactions occurred in 4% of patients treated with Lynparza. These included pneumonia (1.2%), cardiopulmonary failure (0.4%), aspiration pneumonia (0.4%), intestinal diverticulum (0.4%), septic shock (0.4%), Budd-Chiari Syndrome (0.4%), sudden death (0.4%), and acute cardiac failure (0.4%). Serious adverse reactions occurred in 36% of patients receiving Lynparza. The most frequent serious adverse reactions (≥2%) were anemia (9%), pneumonia (4%), pulmonary embolism (2%), fatigue/asthenia (2%), and urinary tract infection (2%). Dose interruptions due to an adverse reaction of any grade occurred in 45% of patients receiving Lynparza; dose reductions due to an adverse reaction occurred in 22% of Lynparza patients. The most frequent adverse reactions leading to dose interruption of Lynparza were anemia (25%) and thrombocytopenia (6%) and the most frequent adverse reaction leading to reduction of Lynparza was anemia (16%). Discontinuation due to adverse reactions occurred in 18% of Lynparza. The adverse reaction that most frequently led to discontinuation of Lynparza was anemia (7%). Tables 14 and 15 summarize the adverse reactions and laboratory abnormalities, respectively, in patients in PROfound. Table 14 Adverse Reactions Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. Reported in ≥10% of Patients in PROfound Adverse Reactions Lynparza tablets n=256 Enzalutamide or abiraterone n=130 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Blood and lymphatic disorders Anemia Includes anemia and hemoglobin decreased. 46 21 15 5 Thrombocytopenia Includes platelet count decreased and thrombocytopenia. 12 4 3 0 Gastrointestinal disorders Nausea 41 1 19 0 Diarrhea 21 1 7 0 Vomiting 18 2 12 1 General disorders and administration site conditions Fatigue (including asthenia) 41 3 32 5 Metabolism and nutrition disorders Decreased appetite 30 1 18 1 Respiratory, thoracic, and mediastinal disorders Cough 11 0 2 0 Dyspnea 10 2 3 0 Clinically relevant adverse reactions that occurred in <10% of patients receiving Lynparza were neutropenia (9%), VTE (7%), dizziness (7%), dysgeusia (7%), dyspepsia (7%), headache (6%), pneumonia (5%), stomatitis (5%), rash (4%), blood creatinine increase (4%), pneumonitis (2%), upper abdominal pain (2%), and hypersensitivity (1%). Table 15 Laboratory Abnormalities Reported in ≥25% of Patients in PROfound Laboratory Parameter Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. Lynparza tablets n This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. = 256 Enzalutamide or abiraterone n =130 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Decrease in hemoglobin 98 13 73 4 Decrease in lymphocytes 62 23 34 13 Decrease in leukocytes 53 4 21 0 Decrease in absolute neutrophil count 34 3 9 0 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone PROpel The safety of Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of patients in the first-line mCRPC setting was investigated in PROpel [see Clinical Studies (14.8) ] . Patients were randomized to receive either Lynparza tablets 300 mg orally twice daily plus abiraterone tablets 1000 mg once daily (Lynparza/abiraterone) (n=398), or placebo plus abiraterone 1000 mg once daily (placebo/abiraterone) (n=396) until disease progression or unacceptable toxicity. Patients in both arms also received either prednisone or prednisolone 5 mg twice daily. Fatal adverse reactions occurred in 6% of patients, including COVID-19 (3%) and pneumonias (0.5%). Serious adverse reactions occurred in 39% of patients. Serious adverse reactions reported in > 2% of patients included anemia (6%), COVID-19 (6%), pneumonia (4.5%), pulmonary embolism (3.5%), and urinary tract infection (3%). Permanent discontinuation of Lynparza due to adverse reactions occurred in 16% of patients treated in the Lynparza with abiraterone arm. The most common adverse reactions which resulted in permanent discontinuation of Lynparza were anemia (4.3%) and pneumonia (1.5%). Dosage interruption of Lynparza due to adverse reactions occurred in 48% of patients treated in the Lynparza with abiraterone arm. The most common (>2%) adverse reactions requiring dosage interruption of Lynparza were anemia (16%), COVID-19 (6%) fatigue (3.5%), nausea (2.8%), pulmonary embolism (2.3%), and diarrhea (2.3%). Dose reduction of Lynparza due to adverse reactions occurred in 21% of patients treated in the Lynparza with abiraterone arm. The most common (>2%) adverse reactions requiring dosage reductions of Lynparza were anemia (11%) and fatigue (2.5%). The most common adverse reactions (≥10%) in patients who received Lynparza/abiraterone were anemia (48%), fatigue (38%), nausea (30%), diarrhea (19%), decreased appetite (16%), lymphopenia (14%), dizziness (14%), and abdominal pain (13%). Tables 16 and 17 summarize adverse reactions and laboratory abnormalities in PROpel, respectively. Table 16 Adverse Reactions (≥10%) in Patients Who Received Lynparza (with a Difference of ≥5% Compared to Placebo) in PROpel Adverse Reactions Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03. Lynparza/abiraterone n=398 Placebo/abiraterone n=396 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Blood and Lymphatic Disorders Anemia Includes anemia, anemia macrocytic, and red blood cell count decreased 48 16 18 3.3 Lymphopenia Includes lymphocyte count decreased and lymphopenia 14 5 6 1.8 General Disorders and Administration Site Conditions Fatigue (including asthenia) 38 2.3 30 1.5 Gastrointestinal Disorders Nausea 30 0.3 14 0.3 Diarrhea 19 1 10 0.3 Abdominal pain Includes abdominal discomfort, abdominal pain, abdominal pain upper, and abdominal pain lower 13 0 7 0.5 Metabolism and nutrition disorders Decreased appetite 16 1 7 0 Nervous System Disorders Dizziness Includes dizziness and vertigo. 14 0.3 7 0 Clinically relevant adverse reactions that occurred in <10% for patients receiving Lynparza plus abiraterone were headache (9%), VTE (8%), rash (7%), dysgeusia (6%), acute kidney injury (3%), stomatitis (2.5%), and pneumonitis (1%). Table 17 Selected Laboratory Abnormalities Reported in ≥20% of Patients in PROpel Laboratory Parameter Lynparza/abiraterone n=398 This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter. Placebo/abiraterone n=396 Grades 1-4 (%) Grades 3-4 (%) Grades 1-4 (%) Grades 3-4 (%) Decrease in hemoglobin 97 12 81 1.3 Decrease in lymphocytes 70 23 49 11 Decrease in platelets 23 1.2 20 0.3 Decrease in absolute neutrophil count 23 5 6 0 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of Lynparza. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hepatobiliary Disorders : Drug-induced liver injury. Immune System Disorders : Hypersensitivity including angioedema. Skin and Subcutaneous Tissue Disorders : Erythema nodosum, rash, dermatitis."],"contraindications":["4 CONTRAINDICATIONS None. None. (4)"],"drug_interactions":["7 DRUG INTERACTIONS • Strong or moderate CYP3A inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce Lynparza dosage. ( 2.4 , 7.2 , 12.3 ) • Strong or moderate CYP3A inducers: Avoid concomitant use. ( 7.2 , 12.3 ) 7.1 Use with Anticancer Agents Clinical studies of Lynparza with other myelosuppressive anticancer agents, including DNA damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity. 7.2 Effect of Other Drugs on Lynparza Strong and Moderate CYP3A Inhibitors Coadministration of CYP3A inhibitors can increase olaparib concentrations, which may increase the risk for adverse reactions [see Clinical Pharmacology (12.3) ] . Avoid coadministration of strong or moderate CYP3A inhibitors. If the strong or moderate inhibitor must be coadministered, reduce the dose of Lynparza [see Dosage and Administration (2.4) ]. Strong and Moderate CYP3A Inducers Concomitant use with a strong or moderate CYP3A inducer decreased olaparib exposure, which may reduce Lynparza efficacy [see Clinical Pharmacology (12.3) ] . Avoid coadministration of strong or moderate CYP3A inducers."],"spl_medguide_table":["<table width=\"100%\"><col width=\"50%\"/><col width=\"50%\"/><tbody><tr><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Medication Guide</content></paragraph><paragraph><content styleCode=\"bold\">Lynparza<sup>&#xAE;</sup> (Lin-par-zah)</content></paragraph><paragraph><content styleCode=\"bold\">(olaparib)</content></paragraph><paragraph><content styleCode=\"bold\">tablets</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is the most important information I should know about Lynparza?</content></paragraph><paragraph><content styleCode=\"bold\">Lynparza may cause serious side effects, including:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).</content> Some people who have received previous treatment with chemotherapy, radiotherapy or certain other medicines for their cancer have developed MDS or AML during treatment with Lynparza. MDS or AML may lead to death.  Symptoms of low blood cell counts are common during treatment with Lynparza, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include:</item></list></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2218;</caption>weakness</item><item><caption>&#x2218;</caption>weight loss</item><item><caption>&#x2218;</caption>fever</item><item><caption>&#x2218;</caption>frequent infections</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2218;</caption>blood in urine or stool</item><item><caption>&#x2218;</caption>shortness of breath</item><item><caption>&#x2218;</caption>feeling very tired</item><item><caption>&#x2218;</caption>bruising or bleeding more easily</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Your healthcare provider will do blood tests to check your blood cell counts:</paragraph><list listType=\"unordered\"><item><caption> </caption><list listType=\"unordered\"><item><caption>&#x2218;</caption>before treatment with Lynparza</item><item><caption>&#x2218;</caption>every month during treatment with Lynparza</item><item><caption>&#x2218;</caption>weekly if you have low blood cell counts that last a long time.</item></list></item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Lung problems (Pneumonitis).</content> Lynparza can cause serious lung problems that can lead to death. Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Blood clots (Venous Thromboembolism, [VTE]).</content> Some people may develop a blood clot in a deep vein, usually in the leg (venous thrombosis), or a clot in the lungs (pulmonary embolism, [PE]) which may be severe or lead to death. Tell your healthcare provider right away if you have any symptoms such as pain or swelling in an extremity, shortness of breath, chest pain, breathing that is more rapid than normal (tachypnea), or heart beats faster than normal (tachycardia). Your healthcare provider will monitor you for these symptoms and may prescribe blood thinner medicine.</item><item><caption>&#x2022;</caption><content styleCode=\"bold\">Liver problems, including Drug-Induced Liver Injury (DILI).</content> People taking Lynparza may develop liver problems which may be severe and can lead to death. Your healthcare provider should do blood tests before and during your treatment with Lynparza. Tell your healthcare provider right away if you notice discomfort on the right side of your stomach-area (abdominal), dark or &#x201C;tea-colored&#x201D; urine, or yellowing of your skin or the whites of your eyes (jaundice).</item></list><paragraph>Your healthcare provide may change your dose, temporarily stop, or permanently stop treatment with Lynparza if you get certain side effects.</paragraph><paragraph>See <content styleCode=\"bold\">&#x201C;What are the possible side effects of LYNPARZA?&#x201D;</content> for more information about side effects.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What is Lynparza?</content></paragraph><paragraph>Lynparza is a prescription medicine used to treat adults who have:</paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>ovarian, fallopian tube, or primary peritoneal cancer:<list listType=\"unordered\"><item><caption>&#x2218;</caption>that is advanced and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Lynparza is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.</item><item><caption>&#x2218;</caption>in combination with another anti-cancer medicine called bevacizumab when your cancer is advanced and homologous recombination deficiency (HRD) positive, which is identified by a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability. Lynparza is used as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy.</item><item><caption>&#x2218;</caption>that has come back and has a certain type of inherited or acquired abnormal BRCA gene. Lynparza is used as maintenance treatment after the cancer has responded to treatment with platinum-based chemotherapy.</item></list></item><item><caption>&#x2022;</caption>human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a certain type of inherited abnormal BRCA gene:<list listType=\"unordered\"><item><caption>&#x2218;</caption>with a high risk of recurrence. Lynparza is given after surgery (treatment after surgery is called adjuvant therapy). You should have received chemotherapy medicines before or after surgery to remove the tumor.</item><item><caption>&#x2218;</caption>that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive breast cancer, you should have either already received hormonal therapy or hormonal therapy is not the right treatment for you.</item></list></item><item><caption>&#x2022;</caption>pancreatic cancer (adenocarcinoma) that has spread to other parts of the body and has a certain type of abnormal inherited BRCA gene. Lynparza is used as maintenance treatment after your cancer has not progressed on at least 16 weeks of your first treatment with platinum-based chemotherapy.</item><item><caption>&#x2022;</caption>metastatic castration-resistant prostate cancer (mCRPC):<list listType=\"unordered\"><item><caption>&#x2218;</caption>with a certain type of inherited or acquired abnormal homologous recombination repair (HRR) genes. Lynparza is used when the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone and has progressed after treatment with other anti-cancer medicines called enzalutamide or abiraterone.</item><item><caption>&#x2218;</caption>with a certain type of abnormal BRCA gene, and the cancer has spread to other parts of the body and no longer responds to a medical or surgical treatment that lowers testosterone. Lynparza is used in combination with another anti-cancer medicine, abiraterone, together with the steroid medicine prednisone or prednisolone.</item></list></item></list><paragraph>Your healthcare provider will perform a test to make sure that Lynparza is right for you.</paragraph><paragraph>It is not known if Lynparza is safe and effective in children.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Before taking Lynparza, tell your healthcare provider about all of your medical conditions, including if you:</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>have lung or breathing problems</item><item><caption>&#x2022;</caption>have kidney problems</item><item><caption>&#x2022;</caption>are pregnant, become pregnant, or plan to become pregnant. Lynparza can harm your unborn baby and may cause loss of pregnancy (miscarriage). <content styleCode=\"bold\">Females who are able to become pregnant:</content><list listType=\"unordered\"><item><caption>&#x2218;</caption>Your healthcare provider may do a pregnancy test before you start treatment with Lynparza.</item><item><caption>&#x2218;</caption>You should use effective birth control (contraception) during treatment with Lynparza and for 6 months after the last dose of Lynparza. Talk to your healthcare provider about birth control methods that may be right for you.</item><item><caption>&#x2218;</caption>Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with Lynparza. <content styleCode=\"bold\">Males</content> with female partners who are pregnant or able to become pregnant:</item><item><caption>&#x2218;</caption>You should use effective contraception during treatment with Lynparza and for 3 months after the last dose of Lynparza.</item><item><caption>&#x2218;</caption>Do not donate sperm during treatment with Lynparza and for 3 months after your last dose.</item></list></item><item><caption>&#x2022;</caption>are breastfeeding or plan to breastfeed. It is not known if Lynparza passes into your breast milk. Do not breastfeed during treatment with Lynparza and for 1 month after receiving the last dose of Lynparza. Talk to your healthcare provider about the best way to feed your baby during this time.</item></list><paragraph><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking Lynparza and certain other medicines may affect how Lynparza works and may cause side effects.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I take Lynparza?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Take Lynparza tablets exactly as your healthcare provider tells you.</item><item><caption>&#x2022;</caption>Your healthcare provider will decide how long you stay on treatment.</item><item><caption>&#x2022;</caption>Do not change your dose or stop taking Lynparza unless your healthcare provider tells you to.</item><item><caption>&#x2022;</caption>Take Lynparza by mouth 2 times a day with or without food. </item><item><caption>&#x2022;</caption>Each dose should be taken about 12 hours apart.</item><item><caption>&#x2022;</caption>Swallow Lynparza tablets whole. Do not chew, crush, dissolve, or divide the tablets.</item><item><caption>&#x2022;</caption>If you are taking Lynparza for early breast cancer and you have HR&#x2011;positive disease, you should continue to take hormonal therapy during your treatment with Lynparza.</item><item><caption>&#x2022;</caption>If you are taking Lynparza for prostate cancer and you are receiving gonadotropin-releasing hormone (GnRH) analog therapy, you should continue with this treatment during your treatment with Lynparza unless you have had a surgery to remove both of your testicles (surgical castration) to lower the amount of testosterone in your body.</item><item><caption>&#x2022;</caption>If you miss a dose of Lynparza, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose.</item><item><caption>&#x2022;</caption>If you take too much Lynparza, call your healthcare provider or go to the nearest hospital emergency room right away.</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What should I avoid while taking Lynparza?</content></paragraph><paragraph>Avoid grapefruit, grapefruit juice, Seville oranges and Seville orange juice during treatment with Lynparza since they may increase the level of Lynparza in your blood.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the possible side effects of Lynparza?</content></paragraph><paragraph><content styleCode=\"bold\">Lynparza may cause serious side effects. </content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption><content styleCode=\"bold\">See &#x201C;What is the most important information I should know about Lynparza?&#x201D;</content></item></list><paragraph><content styleCode=\"bold\">The most common side effects of Lynparza when used alone are:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>tiredness or weakness</item><item><caption>&#x2022;</caption>low red blood cell counts</item><item><caption>&#x2022;</caption>diarrhea</item><item><caption>&#x2022;</caption>loss of appetite</item><item><caption>&#x2022;</caption>headache</item><item><caption>&#x2022;</caption>changes in the way food tastes</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>cough</item><item><caption>&#x2022;</caption>low white blood cell counts</item><item><caption>&#x2022;</caption>shortness of breath</item><item><caption>&#x2022;</caption>dizziness</item><item><caption>&#x2022;</caption>indigestion or heartburn</item><item><caption>&#x2022;</caption>low platelet counts</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of Lynparza when used in combination with bevacizumab are:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>tiredness or weakness</item><item><caption>&#x2022;</caption>low red blood cell counts</item><item><caption>&#x2022;</caption>diarrhea</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>low white blood cell counts</item><item><caption>&#x2022;</caption>urinary tract infection</item><item><caption>&#x2022;</caption>headache</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">The most common side effects of Lynparza when used in combination with abiraterone and prednisone or prednisolone are:</content></paragraph></td></tr><tr><td styleCode=\"Lrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>low red blood cell counts</item><item><caption>&#x2022;</caption>tiredness or weakness</item><item><caption>&#x2022;</caption>diarrhea</item><item><caption>&#x2022;</caption>loss of appetite</item></list></td><td styleCode=\"Rrule \" valign=\"top\"><list listType=\"unordered\"><item><caption>&#x2022;</caption>low white blood cell counts</item><item><caption>&#x2022;</caption>dizziness</item><item><caption>&#x2022;</caption>stomach-area (abdominal) pain</item></list></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nausea or vomiting is common</content> during treatment with Lynparza. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms.</paragraph><paragraph>These are not all of the possible side effects of Lynparza. </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">How should I store Lynparza?</content></paragraph><list listType=\"unordered\"><item><caption>&#x2022;</caption>Store Lynparza at room temperature, between 68&#xB0;F to 77&#xB0;F (20&#xB0;C to 25&#xB0;C).</item><item><caption>&#x2022;</caption>Store Lynparza in the original bottle to protect it from moisture.</item></list><paragraph><content styleCode=\"bold\">Keep Lynparza and all medicines out of reach of children.</content></paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General information about the safe and effective use of Lynparza.</content></paragraph><paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Lynparza for a condition for which it was not prescribed. Do not give Lynparza to other people, even if they have the same symptoms that you have. It may harm them.</paragraph><paragraph>You can ask your pharmacist or healthcare provider for information about Lynparza that is written for health professionals.</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">What are the ingredients in Lynparza?</content></paragraph><paragraph><content styleCode=\"bold\">Active ingredient:</content> olaparib</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Inactive ingredients:</content></paragraph><paragraph>Tablet contains: copovidone, mannitol, colloidal silicon dioxide and sodium stearyl fumarate</paragraph><paragraph>Tablet coating contains: hypromellose, polyethylene glycol 400, titanium dioxide, ferric oxide yellow and ferrosoferric oxide (150 mg tablet only)</paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Lynparza is a registered trademark of the AstraZeneca group of companies.</paragraph><paragraph>&#xA9; AstraZeneca 2025</paragraph><paragraph>Distributed by:</paragraph><paragraph>AstraZeneca Pharmaceuticals LP</paragraph><paragraph>Wilmington, DE 19850</paragraph><paragraph>For more information, call 1-800-236-9933 or go to <linkHtml href=\"http://www.Lynparza.com\">www.Lynparza.com</linkHtml>. </paragraph></td></tr><tr><td colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/></tr></tbody></table>"],"mechanism_of_action":["12.1 Mechanism of Action Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA1/2 , ATM , or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death. In prostate cancer models, PARP1 has been shown to contribute to androgen receptor (AR) activity regulation; the combination of olaparib and AR inhibition resulted in cytotoxicity in vitro and anti-tumor activity in mouse xenograft models."],"recent_major_changes":["Warnings and Precautions ( 5.2 , 5.4 ) 7/2025"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA1/2 , ATM , or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death. In prostate cancer models, PARP1 has been shown to contribute to androgen receptor (AR) activity regulation; the combination of olaparib and AR inhibition resulted in cytotoxicity in vitro and anti-tumor activity in mouse xenograft models. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed. 12.3 Pharmacokinetics The area under the curve (AUC) of olaparib increases approximately proportionally following administration of single doses of 25 mg to 450 mg (0.08 to 1.5 times the recommended dose) and maximal concentrations (C max ) increased slightly less than proportionally for the same dose range. Olaparib showed time-dependent pharmacokinetics and an AUC mean accumulation ratio of 1.8 is observed at steady state following a dose of 300 mg twice daily. The mean (CV%) olaparib C max is 5.4 μg/mL (32%) and AUC is 39.2 μg*h/mL (44%) following a single 300 mg dose. The mean steady state olaparib C max and AUC is 7.6 μg/mL (35%) and 49.2 μg*h/mL (44%), following a dose of 300 mg twice daily. Absorption Following oral administration of olaparib, the median time to peak plasma concentration is 1.5 hours. Effect of Food Co-administration of a high fat and high calorie meal (800-1000 kcal, 50% of the calorie content made up from fat) with olaparib slowed the rate (t max delayed by 2.5 hours) of absorption, but did not significantly alter the extent of olaparib absorption (mean AUC increased by approximately 8%). Distribution The mean (± standard deviation) apparent volume of distribution of olaparib is 158 ± 136 L following a single 300 mg dose of Lynparza. The protein binding of olaparib is approximately 82% in vitro. Elimination The mean (± standard deviation) terminal plasma half-life of olaparib is 14.9 ± 8.2 hours and the apparent plasma clearance is 7.4 ± 3.9 L/h following a single 300 mg dose of Lynparza. Metabolism Olaparib is metabolized by cytochrome P450 (CYP) 3A in vitro. Following an oral dose of radiolabeled olaparib to female patients, unchanged olaparib accounted for 70% of the circulating radioactivity in plasma. It was extensively metabolized with unchanged drug accounting for 15% and 6% of radioactivity in urine and feces, respectively. The majority of the metabolism is attributable to oxidation reactions with a number of the components produced undergoing subsequent glucuronide or sulfate conjugation. Excretion Following a single dose of radiolabeled olaparib, 86% of the dosed radioactivity was recovered within a 7-day collection period, 44% via the urine and 42% via the feces. The majority of the material was excreted as metabolites. Specific Populations Patients with Renal Impairment In a renal impairment trial, the mean AUC increased by 24% and C max by 15%, when olaparib was dosed in patients with mild renal impairment (CLcr=51-80 mL/min defined by the Cockcroft-Gault equation; n=13) and by 44% and 26%, respectively, when olaparib was dosed in patients with moderate renal impairment (CLcr=31-50 mL/min; n=13), compared to those with normal renal function (CLcr ≥81 mL/min; n=12). There was no evidence of a relationship between the extent of plasma protein binding of olaparib and creatinine clearance. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min). Patients with Hepatic Impairment In a hepatic impairment trial, the mean AUC increased by 15% and the mean C max increased by 13% when olaparib was dosed in patients with mild hepatic impairment (Child-Pugh classification A; n=10) and the mean AUC increased by 8% and the mean C max decreased by 13% when olaparib was dosed in patients with moderate hepatic impairment (Child-Pugh classification B; n=8), compared to patients with normal hepatic function (n=13). Hepatic impairment has no effect on the protein binding of olaparib and, therefore, total plasma exposure was representative of free drug. There are no data in patients with severe hepatic impairment (Child-Pugh classification C). Drug Interaction Studies Clinical Studies CYP3A Inhibitors: Concomitant use of itraconazole (strong CYP3A inhibitor) increased olaparib C max by 42% and AUC by 170%. Concomitant use of fluconazole (moderate CYP3A inhibitor) is predicted to increase olaparib C max by 14% and AUC by 121%. CYP3A Inducers : Concomitant use of rifampicin (strong CYP3A inducer) decreased olaparib C max by 71% and AUC by 87%. Concomitant use of efavirenz (moderate CYP3A inducer) is predicted to decrease olaparib C max by 31% and AUC by 60%. In vitro Studies CYP Enzymes : Olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Olaparib is predicted to be a weak CYP3A inhibitor in humans. UGT Enzymes : Olaparib is an inhibitor of UGT1A1. Transporters : Olaparib is an inhibitor of BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1, and MATE2K. Olaparib is a substrate and inhibitor of the efflux transporter P-gp. The potential for olaparib to induce P-gp has not been evaluated."],"indications_and_usage":["1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ]. 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] ."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in approximately 1.2% of patients with various BRCA m, g BRCA m, HRR gene-mutated or HRD-positive cancers exposed to Lynparza and the majority of events had a fatal outcome. Monitor patients for hematological toxicity at baseline and monthly thereafter. Discontinue if MDS/AML is confirmed. (5.1) • Pneumonitis: Occurred in 1.0% of patients exposed to Lynparza, and some cases were fatal. Interrupt treatment if pneumonitis is suspected. Discontinue if pneumonitis is confirmed. (5.2) • Venous thromboembolism (VTE), including severe or fatal pulmonary embolism (PE), occurred in patients treated with Lynparza. VTE occurred in 8% of patients with mCRPC. Monitor patients for signs and symptoms of VTE and PE and treat as medically appropriate. ( 5.3 ) • Hepatotoxicity, Including Drug-induced liver injury (DILI): Occurred in patients treated with Lynparza. If DILI is suspected, interrupt Lynparza. If DILI is confirmed, discontinue treatment. ( 5.4 ) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. ( 5.5 , 8.1 , 8.3 ) 5.1 Myelodysplastic Syndrome/Acute Myeloid Leukemia Myelodysplastic syndrome (MDS)/Acute Myeloid Leukemia (AML) has occurred in patients treated with Lynparza and some cases were fatal. In clinical studies, among 2219 patients with various BRCA m, g BRCA m, HRR gene-mutated or HRD-positive cancers who received Lynparza as a single agent or as part of combination regimen, consistent with approved indications, the cumulative incidence of MDS/AML was approximately 1.2% (26/2219) [see Adverse Reactions (6.1) ]. Of these, 54% (14/26) had a fatal outcome. The median duration of therapy with Lynparza in patients who developed MDS/AML was approximately 2 years (range: < 6 months to > 4 years). All of these patients had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiotherapy. In SOLO1, patients with newly diagnosed advanced BRCA m ovarian cancer, the incidence of MDS/AML was 1.9% (5/260) in patients who received Lynparza and 0.8% (1/130) in patients who received placebo based on an updated analysis. In PAOLA-1, of patients with newly diagnosed advanced ovarian cancer with HRD-positive status, the incidence of MDS/AML was 1.6% (4/255) in patients who received Lynparza and 2.3% (3/131) in the control arm. In SOLO2, patients with BRCA m platinum-sensitive relapsed ovarian cancer, the incidence of MDS/AML was 8% (15/195) in patients who received Lynparza and 4% (4/99) in patients who received placebo. The duration of Lynparza treatment prior to the diagnosis of MDS/AML ranged from 0.6 years to 4.5 years. Do not start Lynparza until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt Lynparza and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Lynparza. 5.2 Pneumonitis Pneumonitis, including severe and fatal cases, has occurred in patients treated with Lynparza. In clinical studies, among patients who received Lynparza as a single agent or as part of a combination regimen [see Error! Hyperlink reference not valid. ] , the incidence of pneumonitis, including fatal cases, was 1.0% (29/2851). If patients present with new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality occurs, interrupt Lynparza treatment and promptly assess the source of the symptoms. If pneumonitis is confirmed, discontinue Lynparza treatment and treat the patient appropriately . 5.3 Venous Thromboembolism Venous thromboembolism (VTE), including severe or fatal pulmonary embolism (PE), occurred in patients treated with Lynparza [see Adverse Reactions (6.1) ] . In the combined data of two randomized, placebo-controlled clinical studies (PROfound and PROpel) in patients with metastatic castration-resistant prostate cancer (N=1180), VTE occurred in 8% of patients who received Lynparza, including pulmonary embolism in 6%. In the control arms, VTE occurred in 2.5% including pulmonary embolism in 1.5%. Monitor patients for clinical signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate, which may include long-term anticoagulation as clinically indicated. 5.4 Hepatotoxicity, Including Drug-Induced Liver Injury Hepatotoxicity, including severe and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Lynparza [see Adverse Reactions (6.2) ] . Evaluate bilirubin and transaminases at baseline and throughout treatment with Lynparza. For patients who develop abnormal liver tests after Lynparza, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold Lynparza. Upon confirmation of DILI, discontinue Lynparza. 5.5 Embryo-Fetal Toxicity Lynparza can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals. In an animal reproduction study, administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily. Apprise pregnant women of the potential hazard to a fetus and the potential risk for loss of the pregnancy. Advise females of reproductive potential to use effective contraception during treatment and for 6 months following the last dose of Lynparza. Based on findings from genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of Lynparza [see Use in Specific Populations ( 8.1 , 8.3 )] ."],"clinical_studies_table":["<table width=\"100%\"><caption>Table 18 Efficacy Results - SOLO-1 (Investigator Assessment)</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">(n=260)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=131)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content><footnote ID=\"_Ref523301911\">Median follow-up of 41 months in both treatment arms.</footnote></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>102 (39%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>96 (73%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NR</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio<footnote ID=\"_Ref136521264\">A value &lt;1 favors Lynparza. Hazard ratio from a Cox proportional hazards model including response to previous platinum chemotherapy (complete response versus partial response) as a covariate.</footnote> (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.30 (0.23, 0.41)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value<footnote ID=\"_Ref136521272\">The p-value is derived from a stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td colspan=\"3\" valign=\"top\"><paragraph>NR not reached; CI Confidence Interval.</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 19 Efficacy Results - PAOLA-1 (HRD-positive status, Investigator Assessment)</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza/bevacizumab</content></paragraph><paragraph><content styleCode=\"bold\">(n=255)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo/bevacizumab</content></paragraph><paragraph><content styleCode=\"bold\">(n=132)</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content><footnote ID=\"_Ref150263660\">Results from a blinded independent review of PFS were consistent with those from investigator-assessed PFS</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>87 (34%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>92 (70%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17.7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio<footnote ID=\"_Ref150263677\">The analysis was performed using an unstratified Cox proportional hazards model.</footnote> (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.33 (0.25, 0.45)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival</content><footnote ID=\"_Ref150258873\">Based on final OS subgroup analysis.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>93 (36%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>69 (52%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>75.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>57.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio&#x2020; (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.62 (0.45, 0.85)</paragraph></td></tr><tr><td colspan=\"3\" valign=\"top\"><paragraph>CI Confidence interval.</paragraph></td></tr></tbody></table>","<table cellpadding=\"0pt\" width=\"100%\"><caption>Table 20 Efficacy Results - SOLO-2 (Investigator Assessment)</caption><col width=\"39%\"/><col width=\"31%\"/><col width=\"31%\"/><thead><tr><th align=\"left\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Lynparza tablets (n=196)</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Placebo (n=99)</content></th></tr></thead><tbody><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><list listType=\"ordered\"><item><caption> </caption> Number of events (%)</item></list></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>107 (55%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>80 (81%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Median, months </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Hazard ratio<footnote ID=\"_Ref49141538\">Hazard ratio from a Cox proportional hazards model including response to last platinum chemotherapy (complete response versus partial response) and time to disease progression in the penultimate platinum-based chemotherapy prior to enrollment (6-12 month versus &gt;12 months) as covariates.</footnote> (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.30 (0.22, 0.41)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> p-value<footnote ID=\"_Ref136521179\">The p-value is derived from a stratified log-rank test.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival</content></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>116 (59)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>65 (66)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Median, months </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>51.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38.8</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Hazard ratio<footnoteRef IDREF=\"_Ref49141538\"/> (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.74 (0.54, 1.00)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> p-value<footnoteRef IDREF=\"_Ref136521179\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.0537</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 21 Early Breast Cancer Stage, Receptor Status, and Grade Scoring Requirements for Study Enrollment<footnote ID=\"_Ref97737829\">Total score of &#x2265;3 required for patients with hormone receptor positive breast cancer.</footnote></caption><col width=\"39%\"/><col width=\"31%\"/><col width=\"30%\"/><thead><tr><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Stage/feature</content></th><th align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Points</content></th></tr></thead><tbody><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Clinical Stage</content></paragraph><paragraph><content styleCode=\"bold\">(pre-treatment)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>I/IIA</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>IIB/IIIA</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>IIIB/IIIC</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Pathologic Stage (post-treatment)</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0/I</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>IIA/IIB/IIIA/IIIB</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>IIIC</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Receptor status</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>ER positive</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>ER negative </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td rowspan=\"2\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nuclear grade</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Nuclear grade 1-2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Nuclear grade 3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 22 Efficacy Results &#x2013; OlympiA</caption><col width=\"52%\"/><col width=\"25%\"/><col width=\"22%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Lynparza tablets</paragraph><paragraph>(N=921)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Placebo</paragraph><paragraph>(N=915)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Invasive Disease Free Survival (IDFS)</content><footnote ID=\"_Ref96081562\">Data from the pre-specified interim analysis (86% of the number of events for the planned final analysis).</footnote></paragraph></td><td styleCode=\"Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Number of events (%) </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>106 (12)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>178 (20)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard ratio (95% CI)<footnote ID=\"_Ref136521056\">Based on the stratified Cox&apos;s Proportional Hazards Model.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.58 (0.46, 0.74)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p&#x2011;value (2&#x2011;sided)<footnote ID=\"_Ref136521063\">p-value from a stratified log-rank test. Compared with the allocated alpha of 0.005 for IDFS and 0.015 for OS.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt; 0.0001</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule \" valign=\"middle\"><paragraph>3-year event-free rate, % (95% CI)<footnote ID=\"_Ref136521071\">Percentage are calculated using Kaplan-Meier estimates.</footnote></paragraph></td><td align=\"center\" valign=\"middle\"><paragraph>86 (82.8, 88.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule \" valign=\"middle\"><paragraph>77 (73.7, 80.1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival</content><footnote ID=\"_Ref136521078\">Data from the pre-specified second interim analysis of OS (at ~330 IDFS events).</footnote></paragraph></td><td styleCode=\"Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>75 (8)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>109 (12)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hazard ratio (95% CI)<footnoteRef IDREF=\"_Ref136521056\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.68 (0.50, 0.91)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>p&#x2011;value (2-sided)<footnoteRef IDREF=\"_Ref136521063\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.0091</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>3-year event-free rate, % (95% CI)<footnoteRef IDREF=\"_Ref136521071\"/></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>93 (90.8, 94.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>89 (86.7, 91)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Toprule \" valign=\"middle\"><paragraph>CI = confidence interval.</paragraph></td></tr></tbody></table>","<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 23 Efficacy Results - OlympiAD (BICR-assessed)</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">(n=205)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemotherapy</content></paragraph><paragraph><content styleCode=\"bold\">(n=97)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>163 (80%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>71 (73%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio (95% CI)<footnote ID=\"_Ref23956920\">Hazard ratio is derived from a stratified log-rank test, stratified by ER, PgR negative versus ER and or PgR positive and prior chemotherapy (yes versus no).</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.58 (0.43, 0.80)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value<footnote ID=\"_Ref136521004\">For PFS, p-value (2-sided) was compared to 0.05.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.0009</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Patients with Measurable Disease</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=167</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=66</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Objective Response Rate (95% CI)<footnote ID=\"_Ref136521012\">Response based on confirmed responses. The confirmed complete response rate was 7.8% for Lynparza compared to 1.5% for chemotherapy arm.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>52% (44, 60)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23% (13, 35)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival</content></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>130 (63%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>62 (64%)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17.1</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Hazard ratio (95% CI)<footnoteRef IDREF=\"_Ref23956920\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.90 (0.66, 1.23)</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 24 Efficacy Results - POLO (BICR-assessed)</caption><col width=\"33%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">(n=92)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">(n=62)</content></paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Progression-Free Survival</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)<footnote ID=\"_Ref40345384\">Number of events: Progression - Lynparza 55, placebo 44; death before BICR-documented progression - Lynparza 5, placebo 0.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>60 (65)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>44 (71)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7.4 (4.1, 11.0)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.8 (3.5, 4.9)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio<footnote ID=\"_Ref136520968\">Hazard ratio, 95% CI, and p-value calculated from a log-rank test. A hazard ratio &lt;1 favors Lynparza.</footnote> (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.53 (0.35, 0.81)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.0035</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival </content></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>61 (66)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>47 (76)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median, months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19.0 (15.3, 26.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19.2 (14.3, 26.1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio&#x2020; (95% CI)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.83 (0.56, 1.22)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value </paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3487</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Patients with Measurable Disease</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=78</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=52</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Objective Response Rate (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23% (14, 34)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12% (4, 23)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Complete response (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 (2.6)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Partial response (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16 (21)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6 (12)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Duration of Response (DOR)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median time in months (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25 (15, NC)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4 (2, NC)</paragraph></td></tr><tr><td colspan=\"3\" valign=\"top\"><paragraph>NC Not calculable.</paragraph></td></tr></tbody></table>","<table styleCode=\"Noautorules\" width=\"100%\"><caption>Table 25 Frequency of Patients with HRR Mutations Enrolled in PROfound</caption><col width=\"34%\"/><col width=\"33%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">HRR Mutation</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cohort A</content></paragraph><paragraph><content styleCode=\"bold\">N=245</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cohort B</content><footnote ID=\"_Ref40330486\">Three patients with single <content styleCode=\"italics\">BRCA2</content> or <content styleCode=\"italics\">ATM</content> gene mutations and 1 patient with co-occurring <content styleCode=\"italics\">BRCA2+CDK12</content> gene mutations were incorrectly assigned to Cohort B.</footnote></paragraph><paragraph><content styleCode=\"bold\">N=142</content></paragraph><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Single mutation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>224 (91)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>135 (95)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> BRCA2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>127 (52)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 (&lt;1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> ATM</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>84 (34)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 (1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> BRCA1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13 (5)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> CDK12</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>89 (63)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> CHEK2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12 (8)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> PPP2R2A</content><footnote ID=\"_Ref136520891\">Lynparza is not indicated for patients with PPP2R2A mutations.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10 (7)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> RAD51B</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5 (4)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> RAD54L</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5 (4)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> PALB2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4 (3)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> BRIP1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3 (2)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> CHEK1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 (1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> BARD1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 (&lt;1)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\"> RAD51D</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 (&lt;1)</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Co-occurring mutation<footnote ID=\"_Ref136520899\">Patients with co-occurring mutations (BRCA1, BRCA2, or ATM plus a Cohort B gene) were assigned to Cohort A.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>21 (9)</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>7 (5)</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 26 Efficacy Results - PROfound (BICR-assessed)</caption><col width=\"39%\"/><col width=\"16%\"/><col width=\"17%\"/><col width=\"13%\"/><col width=\"15%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cohort A</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Cohort A+B</content><footnote ID=\"_Ref40330690\">Although 10 patients with PPP2R2A mutation were included in all analyses of Cohort A+B, Lynparza is not indicated for this population due to unfavorable risk-benefit.</footnote></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets (n=162)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Enzalutamide or Abiraterone acetate (n=83)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets (n=256)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Enzalutamide or Abiraterone acetate (n=131)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Radiological Progression-Free Survival (rPFS)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>106 (65)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>68 (82)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>180 (70)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>99 (76)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median (95% CI), in months </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>7.4 (6.2, 9.3)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.6 (1.9, 3.7)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5.8 (5.5, 7.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3.5 (2.2, 3.7)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio (95% CI)<footnote ID=\"_Ref136520765\">The HR and CI were calculated using a Cox proportional hazards model adjusted for prior taxane use and measurable disease. An HR &lt;1 favors Lynparza 300 mg taken orally twice daily.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.34 (0.25, 0.47)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.49 (0.38, 0.63)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value<footnote ID=\"_Ref136520772\">The analysis was performed using the log-rank test stratified by prior taxane use and measurable disease.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>&lt;0.0001</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Confirmed ORR </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Patients with measurable disease at baseline</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=84</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=43</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> ORR, n (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>28 (33)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1 (2)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> (95% CI)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>(23, 45)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>(0, 12)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value </paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>&lt;0.0001</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=162</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>n=83</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Number of events (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>91 (56)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>57 (69)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Median (95% CI), in months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19.1 (17.4, 23.4)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14.7 (11.9, 18.8)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Hazard ratio (95% CI)<footnoteRef IDREF=\"_Ref136520765\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.69 (0.50, 0.97)</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> p-value<footnoteRef IDREF=\"_Ref136520772\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.0175</paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td colspan=\"5\" valign=\"top\"><paragraph>CI Confidence interval</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 27 Response Rate and Duration of Response by HRR Mutation in Patients with Measurable Disease at Baseline on the Lynparza Arm &#x2013; PROfound (BICR-assessed)</caption><col width=\"37%\"/><col width=\"21%\"/><col width=\"23%\"/><col width=\"19%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">HRR mutation</content><footnote ID=\"_Ref40260349\">No patients with <content styleCode=\"italics\">FANCL</content> or <content styleCode=\"italics\">RAD51C</content> enrolled. Three patients with <content styleCode=\"italics\">PPP2R2A</content> mutations had measurable disease, however, Lynparza is not indicated for patients with <content styleCode=\"italics\">PPP2R2A</content> mutation.</footnote></paragraph></td><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Patients</content></paragraph><paragraph><content styleCode=\"bold\">(N=138)</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Confirmed ORR</content><footnote ID=\"_Ref136521397\">In patients with a single BRCA2 mutation the median duration of response in the Lynparza arm (n=24) was 5.6 months (95% C.I: 5.5, 9.2). In the 3 responders with a single ATM mutation in the Lynparza arm, the duration of response ranged from 5.8+ to 9.0 months. In the 2 responders with a single CDK12 mutation in the Lynparza arm, the duration of response was 3.7 and 7.2 months. + denotes ongoing response.</footnote></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">n (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">95% CI</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Single mutation</content></paragraph></td><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>43</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>24 (56)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>(40, 71)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">ATM </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3 (10)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>(2, 27)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">CDK12 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2 (6)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>(1, 20)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA1 </content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD, PD (4), NE</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">CHEK2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD (2), PD (2)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRIP1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD, PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">PALB2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD, PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">CHEK1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">RAD51B</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">RAD51D</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">RAD54L</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Co-occurring mutations</content></paragraph></td><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2/CDK12</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>PR, SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2/ATM</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD, SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2/BARD1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2/CHEK2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">CDK12/CHEK1</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">CDK12/PALB2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2/CDK12/CHEK2</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>PD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA2/CHEK2/RAD51D</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>SD</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>NA</paragraph></td></tr><tr><td colspan=\"4\" valign=\"top\"><paragraph>PR Partial response; SD Stable disease; PD Progressive disease; NE Not evaluable; NA Not applicable due to small numbers or lack of response.</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 28 Efficacy Results &#x2013; PROpel (Patients with BRCAm)</caption><col width=\"33%\"/><col width=\"34%\"/><col width=\"33%\"/><tbody><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Lynparza/abiraterone</content></paragraph><paragraph>N = 47</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo/abiraterone</content></paragraph><paragraph>N = 38</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Radiological Progression-Free Survival (rPFS)</content><footnote ID=\"_Ref150260484\">Investigator-assessed.</footnote></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Events, n (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>14 (30)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>28 (74)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Median (95% CI), months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>NR (NR, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>8 (6, 15)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Hazard ratio (95% CI)<footnote ID=\"_Ref150260494\">Calculated using an unstratified univariable Cox proportional hazards model.</footnote></paragraph></td><td colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.24 (0.12, 0.45)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Overall Survival (OS) </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Events, n (%)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>13 (28)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>25 (66)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Median (95% CI), months</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>NR (NR, NR)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>23 (18, 34)</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Hazard ratio (95% CI)<footnoteRef IDREF=\"_Ref150260494\"/></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.30 (0.15, 0.59)</paragraph></td></tr><tr><td colspan=\"3\" styleCode=\"Rrule Toprule \" valign=\"top\"><paragraph>NR: Not reached.</paragraph></td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with olaparib. Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian Chinese hamster ovary (CHO) cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of olaparib and indicates potential for genotoxicity in humans. Olaparib was not mutagenic in a bacterial reverse mutation (Ames) test. In a fertility study, female rats received oral olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before mating through the first week of pregnancy. There were no adverse effects on mating and fertility rates at doses up to 15 mg/kg/day (maternal systemic exposures approximately 7% of the human exposure (AUC 0-24h ) at the recommended dose). In a male fertility study, olaparib had no effect on mating and fertility in rats at oral doses up to 40 mg/kg/day following at least 70 days of olaparib treatment (with systemic exposures of approximately 5% of the human exposure (AUC 0-24h ) at the recommended dose)."],"adverse_reactions_table":["<table cellpadding=\"0pt\" width=\"100%\"><caption>Table 2 Adverse Reactions<footnote ID=\"_Ref38455000\">Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.</footnote> in SOLO-1 (&#x2265;10% of Patients Who Received Lynparza)</caption><col width=\"50%\"/><col width=\"13%\"/><col width=\"12%\"/><col width=\"14%\"/><col width=\"12%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n=260</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n=130</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All Grades</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades</content></paragraph><paragraph><content styleCode=\"bold\">3 &#x2013; 4 (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">All</content></paragraph><paragraph><content styleCode=\"bold\">Grades (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades</content></paragraph><paragraph><content styleCode=\"bold\">3 &#x2013; 4 (%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Abdominal pain<footnote ID=\"_Ref38455024\">Includes abdominal pain, abdominal pain lower, abdominal pain upper, abdominal distension, abdominal discomfort, and abdominal tenderness.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Diarrhea<footnote ID=\"_Ref38455040\">Includes colitis, diarrhea, and gastroenteritis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Dyspepsia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Stomatitis<footnote ID=\"_Ref38455058\">Includes stomatitis, aphthous ulcer, and mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Fatigue<footnote ID=\"_Ref38455073\">Includes asthenia, fatigue, lethargy, and malaise.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>67</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic System Disorders </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Anemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Neutropenia<footnote ID=\"_Ref38455087\">Includes neutropenia and febrile neutropenia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Leukopenia<footnote ID=\"_Ref38455102\">Includes leukopenia and white blood cell count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Thrombocytopenia<footnote ID=\"_Ref38455135\">Includes platelet count decreased and thrombocytopenia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Infections and Infestations</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Upper respiratory tract  infection/ influenza/nasopharyngitis/bronchitis </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> UTI<footnote ID=\"_Ref38455252\">Includes urosepsis, urinary tract infection, urinary tract pain, and pyuria.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, Thoracic and Mediastinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Dyspnea<footnote ID=\"_Ref38455271\">Includes dyspnea and dyspnea exertional.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 3 Laboratory Abnormalities Reported in &#x2265;25% of Patients in SOLO-1</caption><col width=\"50%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"12%\"/><col width=\"12%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Laboratory </content></paragraph><paragraph><content styleCode=\"bold\">Parameter</content><footnote ID=\"_Ref522754567\">Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnote ID=\"_Ref522754583\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">=260</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnoteRef IDREF=\"_Ref522754583\"/><content styleCode=\"bold\">=130</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>87</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in mean corpuscular volume</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>87</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>43</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>52</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>67</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in platelets</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Increase in serum creatinine</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 4 Adverse Reactions<footnote ID=\"_Ref40094079\">Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.</footnote> Occurring in &#x2265;10% of Patients Treated with Lynparza/bevacizumab in PAOLA-1 and at &#x2265;5% Frequency Compared to the Placebo/bevacizumab Arm</caption><col width=\"39%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"17%\"/><col width=\"16%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reactions</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza/bevacizumab </content></paragraph><paragraph><content styleCode=\"bold\">n=535</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo/bevacizumab  n=267</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue (including asthenia)<footnote ID=\"_Ref38534392\">Includes asthenia and fatigue.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.9</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anemia<footnote ID=\"_Ref38534400\">Includes anemia, anemia macrocytic, erythropenia, haematocrit decreased, haemoglobin decreased, normochromic anemia, normochromic normocytic anemia, normocytic anemia, and red blood cell count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lymphopenia<footnote ID=\"_Ref66440937\">Includes B-lymphocyte count decreased, lymphocyte count decreased, lymphopenia, and T-lymphocyte count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.1</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Leukopenia<footnote ID=\"_Ref38534415\">Includes leukopenia and white blood cell count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 5 Laboratory Abnormalities Reported in &#x2265;25% of Patients in PAOLA-1<footnote ID=\"_Ref40095548\">Reported within 30 days of the last dose.</footnote></caption><col width=\"47%\"/><col width=\"15%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"12%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Laboratory Parameter</content><footnote ID=\"_Ref40095697\">Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza/bevacizumab  n</content><footnoteRef IDREF=\"_Ref40095697\"/><content styleCode=\"bold\">=535</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo/bevacizumab  n</content><footnote ID=\"_Ref23949789\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">=267</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>79</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>55</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in serum creatinine</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.7</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decrease in platelets</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2.4</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.4</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 6 Adverse Reactions<footnote ID=\"_Ref40196145\">Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0.</footnote> in SOLO-2 (&#x2265;20% of Patients Who Received Lynparza)</caption><col width=\"47%\"/><col width=\"14%\"/><col width=\"13%\"/><col width=\"13%\"/><col width=\"13%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n=195</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n=99</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>76</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Stomatitis<footnote ID=\"_Ref40196200\">Represents grouped term consisting of abscess oral, aphthous ulcer, gingival abscess, gingival disorder, gingival pain, gingivitis, mouth ulceration, mucosal infection, mucosal inflammation, oral candidiasis, oral discomfort, oral herpes, oral infection, oral mucosal erythema, oral pain, oropharyngeal discomfort, and oropharyngeal pain.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue including asthenia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anemia<footnote ID=\"_Ref40196219\">Represents grouped term consisting of anemia, hematocrit decreased, hemoglobin decreased, iron deficiency, mean cell volume increased, and red blood cell count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>44</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Infections and Infestations</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nasopharyngitis/URI/sinusitis/ rhinitis/influenza</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal and Connective Tissue Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Arthralgia/myalgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 7 Laboratory Abnormalities Reported in &#x2265;25% of Patients in SOLO-2</caption><col width=\"33%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"17%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Laboratory Parameter</content><footnote ID=\"_Ref96937793\">Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnote ID=\"_Ref23950038\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">=195 </content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnoteRef IDREF=\"_Ref23950038\"/><content styleCode=\"bold\">=99</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in mean corpuscular volume<footnote ID=\"_Ref23950055\">Represents the proportion of subjects whose mean corpuscular volume was &gt; upper limit of normal (ULN).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>89</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>52</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>83</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>69</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>67</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>51</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in serum creatinine</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>44</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decrease in platelets</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 8 Adverse Reactions<footnote ID=\"_Ref82172317\">Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03</footnote> in OlympiA (&#x2265; 10% of Patients Who Received Lynparza)</caption><col width=\"35%\"/><col width=\"15%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"16%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Adverse Reactions</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n=911</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n=904</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>57</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Stomatitis<footnote ID=\"_Ref82172462\">Includes aphthous ulcer, mouth ulceration, and stomatitis.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4.5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue (including asthenia)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>1.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.7</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anemia<footnote ID=\"_Ref82172560\">Includes anemia, anemia macrocytic, erythropenia, hematocrit decreased, hemoglobin decreased, normochromic anemia, normochromic normocytic anemia, normocytic anemia, and red blood cell count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>24</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3.9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Leukopenia<footnote ID=\"_Ref82172575\">Includes leukopenia and white blood cell count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Neutropenia<footnote ID=\"_Ref82172583\">Includes agranulocytosis, febrile neutropenia, granulocyte count decreased, granulocytopenia, idiopathic neutropenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.8</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dysgeusia<footnote ID=\"_Ref82599506\">Includes dysgeusia and taste disorder.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Dizziness</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Decreased appetite </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 9 Laboratory Abnormalities Reported in &#x2265;25% of Patients in OlympiA</caption><col width=\"25%\"/><col width=\"19%\"/><col width=\"17%\"/><col width=\"20%\"/><col width=\"19%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Laboratory Parameter</content><footnote ID=\"_Ref82695073\">Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnote ID=\"_Ref82174437\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">= 911</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnoteRef IDREF=\"_Ref82174437\"/><content styleCode=\"bold\">=904</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Decrease in lymphocytes </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>77</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>59</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>3.7</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Increase in mean corpuscular volume<footnote ID=\"_Ref82599569\">Represents the proportion of subjects whose mean corpuscular volume was &gt; ULN.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>67</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>4.8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Decrease in hemoglobin </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.9</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>64</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>42</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>0.7</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph>1.1</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 10 Adverse Reactions<footnote ID=\"_Ref37254486\">Graded according to NCI CTCAE v4.0.</footnote> in OlympiAD (&#x2265;20% of Patients Who Received Lynparza)</caption><col width=\"39%\"/><col width=\"14%\"/><col width=\"14%\"/><col width=\"17%\"/><col width=\"16%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reaction</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n=205</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemotherapy</content></paragraph><paragraph><content styleCode=\"bold\">n=91</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>58</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anemia<footnote ID=\"_Ref37254509\">Represents grouped terms consisting of anemia (anemia erythropenia, hematocrit decreased, hemoglobin decreased, and red blood cell count decreased).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>40</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Neutropenia<footnote ID=\"_Ref37254562\">Represents grouped terms consisting of neutropenia (febrile neutropenia, granulocyte count decreased, granulocytopenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>26</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Leukopenia<footnote ID=\"_Ref40362619\">Represents grouped terms consisting of leukopenia (leukopenia and white blood cell count decreased).</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>31</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue (including asthenia)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>36</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Infections and Infestations</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Respiratory tract infection<footnote ID=\"_Ref37254577\">Represents grouped terms consisting of bronchitis, influenza, lower respiratory tract infection, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, upper respiratory tract infection, and upper respiratory tract infection bacterial.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>22</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Headache</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 11 Laboratory Abnormalities Reported in &#x2265;25% of Patients in OlympiAD</caption><col width=\"39%\"/><col width=\"14%\"/><col width=\"17%\"/><col width=\"17%\"/><col width=\"14%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Laboratory Parameter</content><footnote ID=\"_Ref37254723\">Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnote ID=\"_Ref37254748\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">= 205</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Chemotherapy</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnoteRef IDREF=\"_Ref37254748\"/><content styleCode=\"bold\">= 91</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>82</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>66</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>73</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>63</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in mean corpuscular volume<footnote ID=\"_Ref37254809\">Represents the proportion of subjects whose mean corpuscular volume was &gt; ULN.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decrease in platelets</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>33</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>28</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table cellpadding=\"0pt\" width=\"100%\"><caption>Table 12 Adverse Reactions<footnote ID=\"_Ref37767241\">Graded according to NCI CTCAE, version 4.0.</footnote> in POLO (Occurring in &#x2265;10% of Patients who Received Lynparza)</caption><col width=\"46%\"/><col width=\"13%\"/><col width=\"15%\"/><col width=\"12%\"/><col width=\"14%\"/><thead><tr><th align=\"center\" rowspan=\"2\" styleCode=\"Rrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Adverse Reaction</content></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Lynparza tablets</content> <content styleCode=\"bold\">(n=91)</content><footnote ID=\"_Ref37767491\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote></th><th align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><content styleCode=\"bold\">Placebo</content> <content styleCode=\"bold\">(n=60)</content><footnoteRef IDREF=\"_Ref37767491\"/></th></tr><tr><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All Grades (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grades</content> <content styleCode=\"bold\">3 &#x2013; 4 (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">All</content> <content styleCode=\"bold\">Grades</content> <content styleCode=\"bold\"> (%)</content></th><th align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><content styleCode=\"bold\">Grades</content> <content styleCode=\"bold\">3 &#x2013; 4 (%)</content></th></tr></thead><tbody><tr><td colspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Fatigue<footnote ID=\"_Ref37767513\">Includes asthenia and fatigue.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>60</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>35</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>45</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Abdominal pain<footnote ID=\"_Ref37767543\">Includes abdominal pain, abdominal pain upper, and abdominal pain lower.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>37</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>29</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Constipation</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Stomatitis<footnote ID=\"_Ref37767564\">Includes stomatitis and mouth ulceration.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic System Disorders </content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Anemia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Thrombocytopenia<footnote ID=\"_Ref37767584\">Includes platelets count decreased and thrombocytopenia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Neutropenia<footnote ID=\"_Ref37767576\">Includes neutropenia, febrile neutropenia, and neutrophil count decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>8</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and Nutrition Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Musculoskeletal and Connective Tissue Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Back pain</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>17</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Arthralgia</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Skin and Subcutaneous Tissue Disorder</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Rash<footnote ID=\"_Ref37767675\">Includes rash erythematous, rash macular, and rash maculo-papular.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, Thoracic and Mediastinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Dyspnea<footnote ID=\"_Ref37767688\">Includes dyspnea and dyspnea exertional.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Infections and Infestations</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph> Nasopharyngitis</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Dysgeusia</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 13 Laboratory Abnormalities Reported in &#x2265;25% of Patients in POLO</caption><col width=\"46%\"/><col width=\"18%\"/><col width=\"12%\"/><col width=\"12%\"/><col width=\"12%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Laboratory</content></paragraph><paragraph><content styleCode=\"bold\">Parameter</content><footnote ID=\"_Ref38535087\">Patients were allowed to enter POLO with hemoglobin &#x2265;9 g/dL (CTCAE Grade 2) and other laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnote ID=\"_Ref38535114\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">=91</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnoteRef IDREF=\"_Ref38535114\"/><content styleCode=\"bold\">=60</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4 (%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in serum creatinine</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>99</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>85</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>86</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>65</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Increase in mean corpuscular volume<footnote ID=\"_Ref38535130\">Represents the proportion of subjects whose mean corpuscular volume was &gt; ULN.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>71</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>-</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>61</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>27</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in platelets</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>56</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>39</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>50</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>25</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 14 Adverse Reactions<footnote ID=\"_Ref40249232\">Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.</footnote> Reported in &#x2265;10% of Patients in PROfound</caption><col width=\"35%\"/><col width=\"15%\"/><col width=\"17%\"/><col width=\"16%\"/><col width=\"16%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reactions</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n=256</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Enzalutamide or abiraterone </content></paragraph><paragraph><content styleCode=\"bold\">n=130</content></paragraph><paragraph><content styleCode=\"bold\"> </content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and lymphatic disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anemia<footnote ID=\"_Ref40249300\">Includes anemia and hemoglobin decreased.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>46</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>15</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Thrombocytopenia<footnote ID=\"_Ref40249329\">Includes platelet count decreased and thrombocytopenia.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Vomiting</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General disorders and administration site conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue (including asthenia)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>41</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>32</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and nutrition disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Decreased appetite </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Respiratory, thoracic, and mediastinal disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Cough</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Dyspnea</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>2</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 15 Laboratory Abnormalities Reported in &#x2265;25% of Patients in PROfound</caption><col width=\"39%\"/><col width=\"16%\"/><col width=\"14%\"/><col width=\"16%\"/><col width=\"15%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"middle\"><paragraph><content styleCode=\"bold\">Laboratory Parameter</content><footnote ID=\"_Ref96937425\">Patients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza tablets</content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnote ID=\"_Ref40249547\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote><content styleCode=\"bold\">= 256</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Enzalutamide or abiraterone </content></paragraph><paragraph><content styleCode=\"bold\">n</content><footnoteRef IDREF=\"_Ref40249547\"/><content styleCode=\"bold\">=130</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>98</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>73</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>62</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in leukocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>53</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>4</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>21</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>34</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>9</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 16 Adverse Reactions (&#x2265;10%) in Patients Who Received Lynparza (with a Difference of &#x2265;5% Compared to Placebo) in PROpel</caption><col width=\"35%\"/><col width=\"16%\"/><col width=\"15%\"/><col width=\"17%\"/><col width=\"16%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Adverse Reactions</content><footnote ID=\"_Ref136517653\">Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.</footnote></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza/abiraterone n=398</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo/abiraterone n=396</content></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood and Lymphatic Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Anemia<footnote ID=\"_Ref136517698\">Includes anemia, anemia macrocytic, and red blood cell count decreased</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>48</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>18</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>3.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Lymphopenia<footnote ID=\"_Ref136517709\">Includes lymphocyte count decreased and lymphopenia</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.8</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">General Disorders and Administration Site Conditions</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Fatigue (including asthenia)</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>38</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>2.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.5</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Gastrointestinal Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Nausea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>30</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Diarrhea</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>19</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>10</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Abdominal pain<footnote ID=\"_Ref136517721\">Includes abdominal discomfort, abdominal pain, abdominal pain upper, and abdominal pain lower</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>13</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.5</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Metabolism and nutrition disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph> Decreased appetite</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>16</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0</paragraph></td></tr><tr><td colspan=\"5\" styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Nervous System Disorders</content></paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph> Dizziness<footnote ID=\"_Ref136517732\">Includes dizziness and vertigo.</footnote></paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>14</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0.3</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>7</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>","<table width=\"100%\"><caption>Table 17 Selected Laboratory Abnormalities Reported in &#x2265;20% of Patients in PROpel</caption><col width=\"25%\"/><col width=\"19%\"/><col width=\"17%\"/><col width=\"20%\"/><col width=\"18%\"/><tbody><tr><td rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Laboratory Parameter</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Lynparza/abiraterone n=398<footnote ID=\"_Ref136519297\">This number represents the safety population. The derived values in the table are based on the total number of evaluable patients for each laboratory parameter.</footnote></content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Placebo/abiraterone  n=396</content><footnoteRef IDREF=\"_Ref136519297\"/></paragraph></td></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 1-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Grades 3-4</content></paragraph><paragraph><content styleCode=\"bold\">(%)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in hemoglobin</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>97</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>12</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>81</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.3</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in lymphocytes</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>70</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>49</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>11</paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Botrule \" valign=\"top\"><paragraph>Decrease in platelets </paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>1.2</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>20</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>0.3</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>Decrease in absolute neutrophil count</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>23</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>5</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>6</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>0</paragraph></td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). MDS/AML Advise patients to contact their healthcare provider if they experience weakness, feeling tired, fever, weight loss, frequent infections, bruising, bleeding easily, breathlessness, blood in urine or stool, and/or laboratory findings of low blood cell counts, or a need for blood transfusions. This may be a sign of hematological toxicity or a more serious uncommon bone marrow problem called ‘myelodysplastic syndrome’ (MDS) or ‘acute myeloid leukemia’ (AML) which have been reported in patients treated with Lynparza [see Warnings and Precautions (5.1) ] . Pneumonitis Advise patients to contact their healthcare provider if they experience any new or worsening respiratory symptoms including shortness of breath, fever, cough, or wheezing [see Warnings and Precautions (5.2) ] . Venous Thromboembolism Advise patients to immediately report any signs or symptoms of thromboembolism such as pain or swelling in an extremity, shortness of breath, chest pain, tachypnea, and tachycardia [see Warnings and Precautions (5.3) ] . Hepatotoxicity, Including Drug-Induced Liver Injury Inform patients that liver problems, including drug-induced liver injury and abnormalities in liver tests, may develop during Lynparza treatment. Advise patients to contact their healthcare provider immediately if they experience abdominal discomfort, dark urine, or jaundice [see Warnings and Precautions (5.4) ] . Embryo-Fetal Toxicity Inform pregnant women of the risk to a fetus and potential loss of the pregnancy. Advise females to inform their healthcare provider of known or suspected pregnancy [see Use in Specific Populations (8.1) ] . Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for 6 months after the last dose [see Use in Specific Populations (8.3) ] . Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months after receiving the last dose of Lynparza. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of Lynparza [see Warnings and Precautions (5.5) and Use in Specific Populations (8.3) ]. Lactation Advise patients not to breastfeed while taking Lynparza and for one month after receiving the last dose [see Use in Specific Populations (8.2) ] . Drug Interactions Advise patients and caregivers to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products. Inform patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice while taking Lynparza [see Drug Interactions (7.2) ] . Nausea/Vomiting Advise patients that mild or moderate nausea and/or vomiting is very common in patients receiving Lynparza and that they should contact their healthcare provider who will advise on available antiemetic treatment options [see Adverse Reactions (6.1) ] . Distributed by: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 © AstraZeneca 2025"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Recommended dosage is 300 mg taken orally twice daily with or without food. See Full Prescribing Information for the recommended duration. (2.2) • Patients receiving Lynparza for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. (2.2) • For moderate renal impairment (CLcr 31-50 mL/min), reduce Lynparza dosage to 200 mg orally twice daily. (2.5) 2.1 Patient Selection Information on FDA-approved tests for the detection of genetic mutations is available at http://www.fda.gov/companiondiagnostics . Select patients for treatment with Lynparza based on the presence of deleterious or suspected deleterious HRR gene mutations, including BRCA mutations, or genomic instability based on the indication, biomarker, and sample type (Table 1). Table 1 Biomarker Testing for Patient Selection Where testing fails or tissue sample is unavailable/insufficient, or when germline testing is negative, consider using an alternative test, if available. Indication Biomarker Sample type Tumor Blood Plasma (ctDNA) First-line maintenance treatment of germline or somatic BRCAm advanced ovarian cancer BRCA1 m, BRCA2 m X X First-line maintenance treatment of HRD-positive advanced ovarian cancer in combination with bevacizumab BRCA1 m, BRC A2m and/or genomic instability X Maintenance treatment of germline or somatic BRCA m recurrent ovarian cancer BRCA1 m, BRCA2 m X X Adjuvant treatment of gBRCA m HER2-negative high risk early breast cancer gBRCA1 m , gBRCA2 m X g BRCA m HER2-negative metastatic breast cancer gBRCA1 m, gBRCA2 m X First-line maintenance treatment of germline BRCA -mutated metastatic pancreatic adenocarcinoma gBRCA1 m, gBRCA2 m X Germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer ATM m, BRCA1 m , BRCA2 m, BARD1 m, BRIP1 m, CDK12 m, CHEK1 m, CHEK2 m, FANCL m, PALB2 m, RAD51B m, RAD51C m, RAD51D m, RAD54L m X g BRCA1 m, g BRCA2 m X ATM m , BRCA1 m, BRCA2 m X BRCA -mutated metastatic castration-resistant prostate cancer in combination with abiraterone and prednisone or prednisolone BRCA1 m, BRCA2 m X X X 2.2 Recommended Dosage The recommended dosage of Lynparza is 300 mg taken orally twice daily, with or without food. If a patient misses a dose of Lynparza, instruct patient to take their next dose at its scheduled time. Instruct patients to swallow tablets whole. Do not chew, crush, dissolve, or divide tablet. First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Continue treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment. Patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from continuous treatment, can be treated beyond 2 years. First-Line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Continue Lynparza treatment until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment. Patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from continuous Lynparza treatment, can be treated beyond 2 years. When used with Lynparza, the recommended dose of bevacizumab is 15 mg/kg every three weeks. Bevacizumab should be given for a total of 15 months including the period given with chemotherapy and given as maintenance. Refer to the Prescribing Information for bevacizumab when used in combination with Lynparza for more information. Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Continue treatment for a total of 1 year, or until disease recurrence, or unacceptable toxicity, whichever occurs first. Patients receiving Lynparza for hormone receptor positive HER2-negative breast cancer should continue concurrent treatment with endocrine therapy as per current clinical practice guidelines. Germline or Somatic BRCA -mutated Recurrent Ovarian Cancer, Germline BRCA -mutated HER2-negative Metastatic Breast Cancer, Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma, and HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Continue treatment until disease progression or unacceptable toxicity for: • Maintenance treatment of germline or somatic BRCA -mutated recurrent ovarian cancer. • Germline BRCA -mutated HER-2 negative metastatic breast cancer. • First-line maintenance treatment of germline BRCA -mutated metastatic pancreatic adenocarcinoma. • HRR gene-mutated metastatic castration-resistant prostate cancer. BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Continue treatment until disease progression or unacceptable toxicity. When used with Lynparza, the recommended dose of abiraterone is 1000 mg taken orally once daily. Abiraterone should be given in combination with prednisone or prednisolone 5 mg orally twice daily. Refer to the Prescribing Information for abiraterone for dosing information. Patients with mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. 2.3 Dosage Modifications for Adverse Reactions To manage adverse reactions, consider interruption of treatment or dose reduction. The recommended dose reduction is 250 mg taken twice daily. If a further dose reduction is required, then reduce to 200 mg taken twice daily. 2.4 Dosage Modifications for Concomitant Use with Strong or Moderate CYP3A Inhibitors Avoid concomitant use of strong or moderate CYP3A inhibitors with Lynparza. If concomitant use cannot be avoided, reduce Lynparza dosage to: • 100 mg twice daily when used concomitantly with a strong CYP3A inhibitor. • 150 mg twice daily when used concomitantly with a moderate CYP3A inhibitor. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the Lynparza dose taken prior to initiating the CYP3A inhibitor [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ]. 2.5 Dosage Modifications for Renal Impairment Moderate Renal Impairment In patients with moderate renal impairment (CLcr 31-50 mL/min), reduce the Lynparza dosage to 200 mg orally twice daily [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3) ]."],"spl_product_data_elements":["Lynparza olaparib OLAPARIB OLAPARIB COPOVIDONE K25-31 FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE HYPROMELLOSE, UNSPECIFIED MANNITOL POLYETHYLENE GLYCOL 400 SILICON DIOXIDE SODIUM STEARYL FUMARATE TITANIUM DIOXIDE WATER opaque biconvex OP;100;plain Lynparza olaparib OLAPARIB OLAPARIB HYPROMELLOSE, UNSPECIFIED COPOVIDONE K25-31 FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE MANNITOL POLYETHYLENE GLYCOL 400 SILICON DIOXIDE SODIUM STEARYL FUMARATE TITANIUM DIOXIDE WATER grey bi-convex OP150 Lynparza olaparib OLAPARIB OLAPARIB COPOVIDONE K25-31 FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE HYPROMELLOSE, UNSPECIFIED MANNITOL POLYETHYLENE GLYCOL 400 SILICON DIOXIDE SODIUM STEARYL FUMARATE TITANIUM DIOXIDE WATER opaque biconvex OP;100;plain Lynparza olaparib OLAPARIB OLAPARIB HYPROMELLOSE, UNSPECIFIED COPOVIDONE K25-31 FERRIC OXIDE YELLOW FERROSOFERRIC OXIDE MANNITOL POLYETHYLENE GLYCOL 400 SILICON DIOXIDE SODIUM STEARYL FUMARATE TITANIUM DIOXIDE WATER grey bi-convex OP150"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: • 150 mg: green to green/grey, oval, bi-convex, film-coated, with debossment ‘OP150’ on one side and plain on the reverse side. • 100 mg: yellow to dark yellow, oval, bi-convex, film-coated, with debossment ‘OP100’ on one side and plain on the reverse side. Tablets: 150 mg, 100 mg (3)"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise women not to breastfeed. (8.2) 8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1) ] , Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily (see Data ). Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies. Data Animal Data In a fertility and early embryonic development study in female rats, olaparib was administered orally for 14 days before mating through to Day 6 of pregnancy, which resulted in increased post-implantation loss at a dose level of 15 mg/kg/day (with maternal systemic exposures approximately 7% of the human exposure (AUC 0-24h ) at the recommended dose). In an embryo-fetal development study, pregnant rats received oral doses of 0.05 and 0.5 mg/kg/day olaparib during the period of organogenesis. A dose of 0.5 mg/kg/day (with maternal systemic exposures approximately 0.18% of human exposure (AUC 0-24h ) at the recommended dose) caused embryo-fetal toxicities including increased post-implantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital), and diaphragm (hernia). Additional abnormalities or variants included incomplete or absent ossification (vertebrae/sternebrae, ribs, limbs) and other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter, and umbilical artery. Some findings noted above in the eyes, ribs, and ureter were observed at a dose of 0.05 mg/kg/day olaparib at lower incidence. 8.2 Lactation Risk Summary No data are available regarding the presence of olaparib in human milk, or on its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infants from Lynparza, advise a lactating woman not to breastfeed during treatment with Lynparza and for one month after receiving the last dose. 8.3 Females and Males of Reproductive Potential Lynparza can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Pregnancy Testing Verify pregnancy status in females of reproductive potential prior to initiating treatment with Lynparza. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with Lynparza and for 6 months following the last dose. Males Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of Lynparza. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of Lynparza [see Use in Specific Populations (8.1) and Nonclinical Toxicology (13.1) ] . 8.4 Pediatric Use Safety and effectiveness of Lynparza have not been established in pediatric patients. 8.5 Geriatric Use Of the 2901 patients with advanced solid tumors who received Lynparza as a single agent, 680 (23%) patients were aged ≥65 years, and this included 206 (7%) patients who were aged ≥75 years. Thirteen (0.4%) patients were aged ≥85 years. Of the 535 patients with advanced solid tumors who received Lynparza tablets 300 mg orally twice daily in combination with bevacizumab (PAOLA-1), 204 (38%) patients were aged ≥65 years, and this included 31 (6%) patients who were aged ≥75 years. Of the 398 patients with advanced solid tumors who received Lynparza tablets 300 mg orally twice daily in combination with abiraterone and prednisone or prednisolone (PROpel), 268 (67%) patients were aged ≥65 years, and this included 95 (24%) patients who were aged ≥75 years. No overall differences in the safety or effectiveness of Lynparza were observed between these patients and younger patients. 8.6 Renal Impairment No dosage modification is recommended in patients with mild renal impairment (CLcr 51 to 80 mL/min estimated by Cockcroft-Gault). Reduce Lynparza dosage to 200 mg twice daily in patients with moderate renal impairment (CLcr 31 to 50 mL/min) [see Dosage and Administration (2.5) ]. There are no data in patients with severe renal impairment or end-stage disease (CLcr ≤30 mL/min) [see Clinical Pharmacology (12.3) ]. 8.7 Hepatic Impairment No adjustment to the starting dose is required in patients with mild or moderate hepatic impairment (Child-Pugh classification A and B). There are no data in patients with severe hepatic impairment (Child-Pugh classification C) [see Clinical Pharmacology (12.3) ] ."],"dosage_and_administration_table":["<table width=\"100%\"><caption>Table 1 Biomarker Testing for Patient Selection<footnote ID=\"_Ref190355199\">Where testing fails or tissue sample is unavailable/insufficient, or when germline testing is negative, consider using an alternative test, if available.</footnote></caption><col width=\"40%\"/><col width=\"29%\"/><col width=\"9%\"/><col width=\"11%\"/><col width=\"11%\"/><tbody><tr><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Indication</content></paragraph></td><td align=\"center\" rowspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Biomarker</content></paragraph></td><td align=\"center\" colspan=\"2\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Sample type</content></paragraph></td><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Tumor</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Blood</content></paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph><content styleCode=\"bold\">Plasma</content></paragraph><paragraph><content styleCode=\"bold\">(ctDNA)</content></paragraph></td></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>First-line maintenance treatment of germline or somatic <content styleCode=\"italics\">BRCAm</content> advanced ovarian cancer</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">BRCA1</content>m, <content styleCode=\"italics\">BRCA2</content>m</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>First-line maintenance treatment of HRD-positive advanced ovarian cancer in combination with bevacizumab</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">BRCA1</content>m, <content styleCode=\"italics\">BRC</content>A2m and/or genomic instability</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Maintenance treatment of germline or somatic <content styleCode=\"italics\">BRCA</content>m recurrent ovarian cancer</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">BRCA1</content>m, <content styleCode=\"italics\">BRCA2</content>m</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Adjuvant treatment of <content styleCode=\"italics\">gBRCA</content>m HER2-negative high risk early breast cancer</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">gBRCA1</content>m<content styleCode=\"italics\">, gBRCA2</content>m</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>g<content styleCode=\"italics\">BRCA</content>m HER2-negative metastatic breast cancer</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">gBRCA1</content>m, <content styleCode=\"italics\">gBRCA2</content>m</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>First-line maintenance treatment of germline <content styleCode=\"italics\">BRCA</content>-mutated metastatic pancreatic adenocarcinoma</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">gBRCA1</content>m, <content styleCode=\"italics\">gBRCA2</content>m</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td rowspan=\"3\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>Germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">ATM</content>m, <content styleCode=\"italics\">BRCA1</content>m<content styleCode=\"italics\">, BRCA2</content>m, <content styleCode=\"italics\">BARD1</content>m, <content styleCode=\"italics\">BRIP1</content>m, <content styleCode=\"italics\">CDK12</content>m, <content styleCode=\"italics\">CHEK1</content>m, <content styleCode=\"italics\">CHEK2</content>m, <content styleCode=\"italics\">FANCL</content>m, <content styleCode=\"italics\">PALB2</content>m, <content styleCode=\"italics\">RAD51B</content>m, <content styleCode=\"italics\">RAD51C</content>m, <content styleCode=\"italics\">RAD51D</content>m, <content styleCode=\"italics\">RAD54L</content>m</paragraph></td><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\"><content styleCode=\"underline\">g</content>BRCA1</content>m, g<content styleCode=\"italics\">BRCA2</content>m</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph>X</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"/></tr><tr><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"><paragraph><content styleCode=\"italics\">ATM</content>m<content styleCode=\"italics\">, BRCA1</content>m, <content styleCode=\"italics\">BRCA2</content>m</paragraph></td><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"middle\"/><td align=\"center\" styleCode=\"Rrule Lrule Toprule Botrule \" valign=\"top\"><paragraph>X</paragraph></td></tr><tr><td styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA</content>-mutated metastatic castration-resistant prostate cancer in combination with abiraterone and prednisone or prednisolone </paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph><content styleCode=\"italics\">BRCA1</content>m, <content styleCode=\"italics\">BRCA2</content>m</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>X</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>X</paragraph></td><td align=\"center\" styleCode=\"Rrule Botrule Lrule Toprule \" valign=\"top\"><paragraph>X</paragraph></td></tr></tbody></table>"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 100 mg NDC 0310-0668-60 Lynparza ® (olaparib) tablets 100 mg Dispense accompanying Medication Guide to each patient. 60 Tablets Rx only AstraZeneca lynparza_100mg_60tablet_bottle_label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 150 mg NDC 0310-0679-12 Lynparza ® (olaparib) tablets 150 mg Dispense accompanying Medication Guide to each patient. 120 Tablets Rx only AstraZeneca lynparza_150mg_120_tablet_bottle_label","Package/Label Display Panel NDC 0310-0569-60 Lynparza (olaparib) tablets 100 mg Dispense accompanying Medication Guide to each Patient. 60 Tablets Rx Only AstraZeneca 100_mg","Package/Label Display Panel NDC 0310-0578-60 Lynparza (olaparib) tablets 150 mg Dispense accompanying Medication Guide to each patient. 60 Tablets Rx only AstraZeneca 150_mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with olaparib. Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian Chinese hamster ovary (CHO) cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of olaparib and indicates potential for genotoxicity in humans. Olaparib was not mutagenic in a bacterial reverse mutation (Ames) test. In a fertility study, female rats received oral olaparib at doses of 0.05, 0.5, and 15 mg/kg/day for at least 14 days before mating through the first week of pregnancy. There were no adverse effects on mating and fertility rates at doses up to 15 mg/kg/day (maternal systemic exposures approximately 7% of the human exposure (AUC 0-24h ) at the recommended dose). In a male fertility study, olaparib had no effect on mating and fertility in rats at oral doses up to 40 mg/kg/day following at least 70 days of olaparib treatment (with systemic exposures of approximately 5% of the human exposure (AUC 0-24h ) at the recommended dose)."]},"tags":[{"label":"Poly(ADP-Ribose) Polymerase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Poly [ADP-ribose] polymerase 2","category":"target"},{"label":"PARP2","category":"gene"},{"label":"PARP1","category":"gene"},{"label":"TNKS2","category":"gene"},{"label":"L01XK01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"BRCA mutation-positive and HER2-negative breast cancer","category":"indication"},{"label":"Epithelial tumor of ovary","category":"indication"},{"label":"Hormone refractory prostate cancer","category":"indication"},{"label":"Human epidermal growth factor 2 negative carcinoma of breast","category":"indication"},{"label":"Malignant tumor of ovary","category":"indication"},{"label":"Malignant tumor of pancreas","category":"indication"},{"label":"Astrazeneca","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Poly(ADP-ribose) Polymerase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"4519 reports"},{"date":"","signal":"MALIGNANT NEOPLASM PROGRESSION","source":"FDA FAERS","actionTaken":"1959 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1694 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1595 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"1522 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"873 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"682 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"644 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"582 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"554 reports"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"60%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"55%","severity":"serious","_validated":true},{"effect":"Anemia","drugRate":"36%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"32%","severity":"serious","_validated":true},{"effect":"Diarrhea","drugRate":"24%","severity":"common","_validated":true},{"effect":"Decreased appetite","drugRate":"22%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"16%","severity":"common","_validated":true},{"effect":"Dysgeusia","drugRate":"15%","severity":"common","_validated":true},{"effect":"Cough","drugRate":"15%","severity":"common","_validated":true},{"effect":"Neutropenia","drugRate":"14%","severity":"common","_validated":true},{"effect":"Dyspnea","drugRate":"14%","severity":"common","_validated":true},{"effect":"Dizziness","drugRate":"12%","severity":"common","_validated":true},{"effect":"Dyspepsia","drugRate":"12%","severity":"common","_validated":true},{"effect":"Leukopenia","drugRate":"11%","severity":"common","_validated":true},{"effect":"Thrombocytopenia","drugRate":"10%","severity":"common","_validated":true},{"effect":"Abdominal pain","drugRate":"45%","severity":"serious","_validated":true},{"effect":"Constipation","drugRate":"28%","severity":"common","_validated":true},{"effect":"Stomatitis","drugRate":"11%","severity":"mild","_validated":true},{"effect":"Upper respiratory tract infection","drugRate":"28%","severity":"common","_validated":true}],"specialPopulations":{"Lactation":"No data are available regarding the presence of olaparib in human milk, or on its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infants from Lynparza, advise lactating woman not to breastfeed during treatment with Lynparza and for one month after receiving the last dose.","Pregnancy":"Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily (see Data). Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy.","Geriatric use":"Of the 2901 patients with advanced solid tumors who received Lynparza as single agent, 680 (23%) patients were aged >=65 years, and this included 206 (7%) patients who were aged >=75 years. Thirteen (0.4%) patients were aged >=85 years. Of the 535 patients with advanced solid tumors who received Lynparza tablets 300 mg orally twice daily in combination with bevacizumab, 204 (38%) patients were aged >=65 years, and this included 31 (6%) patients who were aged >=75 years. No over","Paediatric use":"Safety and effectiveness of Lynparza have not been established in pediatric patients."}},"trials":[],"aliases":[],"company":"AstraZeneca","patents":[{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Aug 12, 2027","useCode":"U-2482","territory":"US","drugProduct":false,"patentNumber":"8143241","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Aug 4, 2031","useCode":"U-2101","territory":"US","drugProduct":false,"patentNumber":"8859562","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Aug 12, 2027","useCode":"U-3631","territory":"US","drugProduct":false,"patentNumber":"8071579","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Oct 25, 2041","useCode":"U-3929","territory":"US","drugProduct":false,"patentNumber":"11970530","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Oct 7, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11975001","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Oct 7, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"11633396","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Dec 31, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8475842","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Oct 7, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12048695","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Oct 7, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12178816","drugSubstance":false},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Sep 8, 2027","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7449464","drugSubstance":true},{"applNo":"N208558","source":"FDA Orange Book","status":"Active","expires":"Oct 7, 2029","useCode":"","territory":"US","drugProduct":true,"patentNumber":"12144810","drugSubstance":false},{"type":"Compound","number":"8247416","applicant":"ASTRAZENECA PHARMACEUTICALS LP","territory":"US","tradeName":"LYNPARZA","expiryDate":"2028-09-24"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=olaparib","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:43:02.510056+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:42:51.552257+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Olaparib","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:43:10.841139+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:09.490002+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:43:02.533272+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:42:49.926041+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=olaparib","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:10.272871+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:48.537939+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:48.537990+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:48.538006+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:43:11.837443+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: PARP 1, 2 and 3 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:10.841065+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL521686/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:10.744623+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208558","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:42:48.538015+00:00"}},"allNames":"azd2281, lynparza","offLabel":[],"synonyms":["olaparib","lynparza","AZD2281"],"timeline":[{"date":"2014-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ASTRAZENECA PHARMS to Astrazeneca"},{"date":"2014-10-23","type":"positive","source":"DrugCentral","milestone":"EMA approval"},{"date":"2014-12-19","type":"positive","source":"DrugCentral","milestone":"FDA approval (Astrazeneca Pharms)"},{"date":"2018-01-19","type":"positive","source":"DrugCentral","milestone":"PMDA approval (AstraZeneca KK)"},{"date":"2026-05-31","type":"negative","source":"FDA Orange Book","milestone":"I-914 exclusivity expires"},{"date":"2026-12-27","type":"negative","source":"FDA Orange Book","milestone":"ODE-283 exclusivity expires"},{"date":"2027-05-08","type":"negative","source":"FDA Orange Book","milestone":"ODE-306 exclusivity expires"},{"date":"2027-09-08","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7449464 expires"}],"aiSummary":"Lynparza (olaparib) is a small molecule Poly(ADP-Ribose) Polymerase Inhibitor developed by AstraZeneca, targeting Poly [ADP-ribose] polymerase 2. It was FDA-approved in 2014 for various cancer indications, including BRCA mutation-positive breast and ovarian cancers. Lynparza is patented and has no generic manufacturers. Key safety considerations include myelosuppression, nausea, and fatigue. It is a targeted therapy that works by blocking the repair of DNA damage in cancer cells.","brandName":"Lynparza","ecosystem":[{"indication":"BRCA mutation-positive and HER2-negative breast cancer","otherDrugs":[],"globalPrevalence":1800000},{"indication":"Epithelial tumor of ovary","otherDrugs":[],"globalPrevalence":null},{"indication":"Hormone refractory prostate cancer","otherDrugs":[{"name":"darolutamide","slug":"darolutamide","company":"Bayer Healthcare Pharmaceuticals Inc"},{"name":"niraparib","slug":"niraparib","company":"Tesaro Inc"}],"globalPrevalence":null},{"indication":"Human epidermal growth factor 2 negative carcinoma of breast","otherDrugs":[{"name":"abemaciclib","slug":"abemaciclib","company":"Eli Lilly And Co"},{"name":"palbociclib","slug":"palbociclib","company":"Pfizer Inc"}],"globalPrevalence":null},{"indication":"Malignant tumor of ovary","otherDrugs":[{"name":"altretamine","slug":"altretamine","company":"Eisai Inc"},{"name":"carboplatin","slug":"carboplatin","company":""},{"name":"cisplatin","slug":"cisplatin","company":"Hq Spclt Pharma"},{"name":"doxorubicin","slug":"doxorubicin","company":""}],"globalPrevalence":null},{"indication":"Malignant tumor of pancreas","otherDrugs":[],"globalPrevalence":null},{"indication":"Malignant tumor of peritoneum","otherDrugs":[{"name":"bevacizumab","slug":"bevacizumab","company":"Genentech"},{"name":"niraparib","slug":"niraparib","company":"Tesaro Inc"},{"name":"paclitaxel","slug":"paclitaxel","company":"Hq Spclt Pharma"}],"globalPrevalence":null}],"mechanism":{"target":"Poly [ADP-ribose] polymerase 2","novelty":"Follow-on","targets":[{"gene":"PARP2","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 2","protein":"Poly [ADP-ribose] polymerase 2"},{"gene":"PARP1","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 1","protein":"Poly [ADP-ribose] polymerase 1"},{"gene":"TNKS2","source":"DrugCentral","target":"Tankyrase-2","protein":"Tankyrase-2"},{"gene":"PARP3","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 3","protein":"Poly [ADP-ribose] polymerase 3"},{"gene":"PARP4","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 4","protein":"Poly [ADP-ribose] polymerase 4"},{"gene":"PARP10","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 10","protein":"Poly [ADP-ribose] polymerase 10"},{"gene":"TNKS","source":"DrugCentral","target":"Tankyrase-1","protein":"Tankyrase-1"},{"gene":"PARP6","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 6","protein":"Poly [ADP-ribose] polymerase 6"},{"gene":"PARP16","source":"DrugCentral","target":"Mono [ADP-ribose] polymerase PARP16","protein":"Mono [ADP-ribose] polymerase PARP16"},{"gene":"PARP12","source":"DrugCentral","target":"Poly [ADP-ribose] polymerase 12","protein":"Poly [ADP-ribose] polymerase 12"}],"moaClass":"Poly(ADP-Ribose) Polymerase Inhibitors","modality":"Small Molecule","drugClass":"Poly(ADP-Ribose) Polymerase Inhibitor [EPC]","explanation":"Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.","oneSentence":"Lynparza blocks the repair of DNA damage in cancer cells by inhibiting the enzyme PARP.","technicalDetail":"Lynparza (olaparib) is a potent inhibitor of PARP1 and PARP2 enzymes, which play a crucial role in the repair of single-strand DNA breaks through the base excision repair pathway."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Olaparib","title":"Olaparib","extract":"Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.","wiki_history":"==History==\nOlaparib was developed and first dosed into patients by the UK-based biotechnology company, KuDOS Pharmaceuticals, that was founded by Stephen Jackson of Cambridge University, UK. Since KuDOS was acquired by AstraZeneca in 2006, the drug has undergone clinical development by AstraZeneca and Merck & Co.\n\nIn December 2014, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved olaparib as monotherapy. The EMA public assessment report, which utilized the same phase II trial data, made reference to both \"high grade serous ovarian cancers\" and to the use of olaparib \"not later than 8 weeks after a course of platinum-based medicines, when the tumour was diminishing in size or had completely disappeared\".\n\nThe FDA approval was for germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. In January 2018, olaparib became the first PARP inhibitor to be approved by the FDA for gBRCAm metastatic breast cancer.\n\nIn breast cancer, olaparib is approved for gBRCAm HER2-negative metastatic breast cancer patients who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. If patients have hormone receptor positive cancer, they should have received endocrine therapy where appropriate. This approval was based on the OlympiAD randomised phase III trial, which showed a progression-free survival benefit for patients treated with olaparib compared to conventional chemotherapy.\n\nIn August 2017, olaparib tablets were approved in the United States for the maintenance treatment of adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. The formulation was changed from capsules to tablets and the capsules were phased out in the United States. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BR"},"commercial":{"launchDate":"2014","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2014-12-19, ASTRAZENECA PHARMS)","annualRevenue":2600,"revenueSource":"Verified: AstraZeneca AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4907","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=olaparib","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=olaparib","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Olaparib","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:13:58.617828","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:16.900372+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"niraparib","drugSlug":"niraparib","fdaApproval":"2017-03-27","patentExpiry":"Mar 27, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rucaparib","drugSlug":"rucaparib","fdaApproval":"2016-12-19","patentExpiry":"Feb 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"talazoparib tosylate","drugSlug":"talazoparib-tosylate","fdaApproval":"2018-10-16","patentExpiry":"Oct 20, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"I-914","date":"May 31, 2026"},{"code":"ODE-283","date":"Dec 27, 2026"},{"code":"ODE-306","date":"May 8, 2027"},{"code":"I-914","date":"May 31, 2026"},{"code":"ODE-283","date":"Dec 27, 2026"},{"code":"ODE-306","date":"May 8, 2027"}],"genericName":"olaparib","indications":{"approved":[{"name":"BRCA mutation-positive and HER2-negative breast cancer","source":"DrugCentral","snomedId":767444009,"regulator":"FDA","eligibility":{"age":"adult","stage":"metastatic","biomarkers":"deleterious or suspected deleterious germline BRCA-mutated, HER2-negative","prior treatment":"chemotherapy in the neoadjuvant, adjuvant or metastatic setting","additional criteria":"patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy"},"usPrevalence":null,"globalPrevalence":1800000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Epithelial tumor of ovary","source":"DrugCentral","snomedId":237057005,"regulator":"FDA","eligibility":{"age":"adult","stage":"advanced, recurrent","biomarkers":"deleterious or suspected deleterious germline or somatic BRCA-mutated, homologous recombination deficiency (HRD)-positive status","prior treatment":"first-line platinum-based chemotherapy","additional criteria":"complete or partial response to platinum-based chemotherapy"}},{"name":"Hormone refractory prostate cancer","source":"DrugCentral","snomedId":427492003,"regulator":"FDA","eligibility":{"age":"adult","stage":"metastatic","biomarkers":"deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated","prior treatment":"enzalutamide or abiraterone","additional criteria":"metastatic castration-resistant prostate cancer (mCRPC)"}},{"name":"Human epidermal growth factor 2 negative carcinoma of breast","source":"DrugCentral","snomedId":431396003,"regulator":"FDA","eligibility":{"age":"adult","stage":"metastatic","biomarkers":"deleterious or suspected deleterious germline BRCA-mutated, HER2-negative","prior treatment":"chemotherapy in the neoadjuvant, adjuvant or metastatic setting","additional criteria":"patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy"}},{"name":"Malignant tumor of ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA","eligibility":{"age":"adult","stage":"advanced, recurrent","biomarkers":"deleterious or suspected deleterious germline or somatic BRCA-mutated, homologous recombination deficiency (HRD)-positive status","prior treatment":"first-line platinum-based chemotherapy","additional criteria":"complete or partial response to platinum-based chemotherapy"}},{"name":"Malignant tumor of pancreas","source":"DrugCentral","snomedId":363418001,"regulator":"FDA","eligibility":{"age":"adult","stage":"metastatic","biomarkers":"deleterious or suspected deleterious germline BRCA-mutated","prior treatment":"first-line platinum-based chemotherapy regimen","additional criteria":"disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy regimen"}},{"name":"Malignant tumor of peritoneum","source":"DrugCentral","snomedId":363492001,"regulator":"FDA","eligibility":{"age":"adult","stage":"advanced, recurrent","biomarkers":"deleterious or suspected deleterious germline or somatic BRCA-mutated, homologous recombination deficiency (HRD)-positive status","prior treatment":"first-line platinum-based chemotherapy","additional criteria":"complete or partial response to platinum-based chemotherapy"}}],"offLabel":[],"pipeline":[]},"currentOwner":"Astrazeneca","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"niraparib","brandName":"niraparib","genericName":"niraparib","approvalYear":"2017","relationship":"same-class"},{"drugId":"rucaparib","brandName":"rucaparib","genericName":"rucaparib","approvalYear":"2016","relationship":"same-class"},{"drugId":"talazoparib-tosylate","brandName":"talazoparib tosylate","genericName":"talazoparib tosylate","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2017-02-06","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":387,"completionDate":"2023-02-15"},{"nctId":"NCT01874353","phase":"PHASE3","title":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2013-09-03","conditions":["Platinum Sensitive","BRCA Mutated","Relapsed Ovarian Cancer","Following Complete or Partial Response to Platinum Based Chemotherapy"],"enrollment":327,"completionDate":"2025-12-31"},{"nctId":"NCT02477644","phase":"PHASE3","title":"Platine, Avastin and OLAparib in 1st Line","status":"COMPLETED","sponsor":"Arcagy Research","isPivotal":true,"startDate":"2015-05-06","conditions":["Ovarian Cancer"],"enrollment":806,"completionDate":"2022-03-22"},{"nctId":"NCT01844986","phase":"PHASE3","title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2013-08-26","conditions":["Newly Diagnosed","Advanced Ovarian Cancer","FIGO Stage III-IV","BRCA Mutation","Complete Response","Partial Response","First Line Platinum Chemotherapy"],"enrollment":450,"completionDate":"2028-08-29"},{"nctId":"NCT02184195","phase":"PHASE3","title":"Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2014-12-16","conditions":["Germline BRCA1/2 Mutations and","Metastatic Adenocarcinoma of the Pancreas"],"enrollment":154,"completionDate":"2023-01-27"},{"nctId":"NCT00753545","phase":"PHASE2","title":"Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2008-08-28","conditions":["Ovarian Cancer"],"enrollment":265,"completionDate":"2023-10-12"},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":["Gynecologic Cancers","Platinum-Sensitive Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer (PSOC)"],"enrollment":377,"completionDate":"2028-02"},{"nctId":"NCT04585958","phase":"PHASE1","title":"Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-21","conditions":["Metastatic Malignant Solid Neoplasm","Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":55,"completionDate":"2026-12-31"},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":["Advanced Malignant Solid Neoplasm","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Locally Advanced Malignant Solid Neoplasm","Malignant Female Reproductive System Neoplasm","Metastatic HER2-Negative Breast Carcinoma","Metastatic Malignant Solid Neoplasm","Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Unresectable HER2-Negative Breast Carcinoma","Unresectable Malignant Solid Neoplasm"],"enrollment":2900,"completionDate":"2030-07-01"},{"nctId":"NCT02893917","phase":"PHASE2","title":"Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-11","conditions":["Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma With Neuroendocrine Differentiation","Stage IV Prostate Adenocarcinoma AJCC v7"],"enrollment":90,"completionDate":"2026-06-18"},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":720,"completionDate":"2027-01-31"},{"nctId":"NCT04548752","phase":"PHASE2","title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-22","conditions":["Metastatic Pancreatic Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8"],"enrollment":88,"completionDate":"2026-10-01"},{"nctId":"NCT04858334","phase":"PHASE2","title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-22","conditions":["Pancreatic Acinar Cell Carcinoma","Pancreatic Adenosquamous Carcinoma","Pancreatic Squamous Cell Carcinoma","Resectable Pancreatic Acinar Cell Carcinoma","Resectable Pancreatic Adenocarcinoma","Resectable Pancreatic Adenosquamous Carcinoma","Resectable Pancreatic Carcinoma"],"enrollment":152,"completionDate":"2027-10-31"},{"nctId":"NCT05554328","phase":"PHASE2","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-25","conditions":["Recurrent Endometrial Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma"],"enrollment":165,"completionDate":"2028-10-01"},{"nctId":"NCT04034927","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":["Fallopian Tube Endometrioid Tumor","Fallopian Tube High Grade Serous Adenocarcinoma","Malignant Ovarian Endometrioid Tumor","Ovarian High Grade Serous Adenocarcinoma","Platinum-Sensitive Fallopian Tube Carcinoma","Platinum-Sensitive Ovarian Carcinoma","Platinum-Sensitive Primary Peritoneal Carcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian Serous Adenocarcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma"],"enrollment":61,"completionDate":"2027-02-21"},{"nctId":"NCT03953898","phase":"PHASE2","title":"Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-04","conditions":["Acute Myeloid Leukemia","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Acute Myeloid Leukemia Post Cytotoxic Therapy","Recurrent Acute Myeloid Leukemia","Recurrent Myelodysplastic Syndrome","Refractory Acute Myeloid Leukemia","Refractory Myelodysplastic Syndrome"],"enrollment":14,"completionDate":"2027-03-04"},{"nctId":"NCT05411094","phase":"PHASE1","title":"Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-22","conditions":["Locally Advanced Pancreatic Carcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Unresectable Pancreatic Carcinoma"],"enrollment":18,"completionDate":"2028-07-01"},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":["Advanced Adrenal Gland Pheochromocytoma","Advanced Paraganglioma","Metastatic Adrenal Gland Pheochromocytoma","Metastatic Paraganglioma","Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8","Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8","Unresectable Adrenal Gland Pheochromocytoma","Unresectable Paraganglioma"],"enrollment":46,"completionDate":"2028-03-01"},{"nctId":"NCT03375307","phase":"PHASE2","title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-03","conditions":["Advanced Bladder Carcinoma","Advanced Genitourinary System Carcinoma","Metastatic Bladder Carcinoma","Metastatic Genitourinary System Carcinoma","Stage III Bladder Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8"],"enrollment":60,"completionDate":"2026-12-16"},{"nctId":"NCT03598257","phase":"PHASE2","title":"Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-18","conditions":["Breast Inflammatory Carcinoma"],"enrollment":300,"completionDate":"2027-06-01"},{"nctId":"NCT04633239","phase":"PHASE1","title":"Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-02","conditions":["Recurrent Ovarian High Grade Serous Adenocarcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma"],"enrollment":42,"completionDate":"2026-11-01"},{"nctId":"NCT02484404","phase":"PHASE1,PHASE2","title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-29","conditions":["Colorectal Neoplasms","Breast Neoplasms"],"enrollment":268,"completionDate":"2026-07-01"},{"nctId":"NCT06580314","phase":"PHASE3","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-03-12","conditions":["Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube High Grade Serous Adenocarcinoma","FIGO Stage III Ovarian Cancer 2014","FIGO Stage IV Ovarian Cancer 2014","Ovarian Carcinoma","Ovarian High Grade Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma"],"enrollment":880,"completionDate":"2034-12-31"},{"nctId":"NCT06353386","phase":"PHASE1,PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":["Prostatic Neoplasms, Castration-Resistant"],"enrollment":220,"completionDate":"2029-01-15"},{"nctId":"NCT03787680","phase":"PHASE2","title":"Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-10-31","conditions":["Prostate Cancer"],"enrollment":49,"completionDate":"2028-08"},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":["Epithelial Ovarian Cancer","Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma"],"enrollment":500,"completionDate":"2032-10-31"},{"nctId":"NCT07486687","phase":"PHASE3","title":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2026-04","conditions":["Triple Negative Breast Cancer (TNBC), Early Setting","Early Stage Triple-Negative Breast Carcinoma","Triple -Negative Breast Cancer","Breast Cancer Stage II","Breast Cancer Stage III"],"enrollment":1000,"completionDate":"2036-04"},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":["Lymphoma, Non-Hodgkin","Multiple Myeloma","Advanced Solid Tumors"],"enrollment":4200,"completionDate":"2028-12-31"},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":["Prostate Cancer"],"enrollment":1247,"completionDate":"2025-03-14"},{"nctId":"NCT03462342","phase":"PHASE2","title":"Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2018-03-09","conditions":["High Grade Serous Carcinoma"],"enrollment":123,"completionDate":"2025-07-21"},{"nctId":"NCT07475923","phase":"","title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-26","conditions":["Molecular Surveillance","Breast Cancer","ctDNA","MRD","Observational Study"],"enrollment":300,"completionDate":"2033-12-31"},{"nctId":"NCT05340413","phase":"PHASE2","title":"Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2022-03-25","conditions":["HER2-negative Breast Cancer","Metastatic Breast Cancer","Triple Negative Breast Cancer"],"enrollment":65,"completionDate":"2025-02-03"},{"nctId":"NCT03486873","phase":"PHASE3","title":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-08-21","conditions":["Solid Tumors","Hematologic Malignancies"],"enrollment":3500,"completionDate":"2043-08-04"},{"nctId":"NCT03742245","phase":"PHASE1","title":"Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2019-06-11","conditions":["Breast Cancer Metastatic","Breast Cancer"],"enrollment":28,"completionDate":"2026-12-01"},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":["Breast Neoplasms","Breast Cancer"],"enrollment":372,"completionDate":"2034-12-31"},{"nctId":"NCT05677308","phase":"","title":"LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-07","conditions":["Breast Cancer"],"enrollment":61,"completionDate":"2026-02-18"},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":["Breast Neoplasms","Breast Cancer","Breast Tumors","Angiosarcoma","TNBC - Triple-Negative Breast Cancer","HER2-positive Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Hormone Receptor Negative Tumor","Early-stage Breast Cancer","Locally Advanced Breast Cancer"],"enrollment":5000,"completionDate":"2031-12"},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":["Ovarian Cancer"],"enrollment":358,"completionDate":"2026-01-19"},{"nctId":"NCT05952453","phase":"PHASE2","title":"Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-17","conditions":["Ovarian Cancer"],"enrollment":20,"completionDate":"2030-12-30"},{"nctId":"NCT05171816","phase":"PHASE3","title":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-06-24","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":110,"completionDate":"2026-04-28"},{"nctId":"NCT05286827","phase":"PHASE2","title":"Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-14","conditions":["Pancreatic Acinar Cell Carcinoma"],"enrollment":5,"completionDate":"2025-09-25"},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":["Solid Tumors","Cisplatin Nephrotoxicity"],"enrollment":46,"completionDate":"2026-10-30"},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":["Ovarian Cancer"],"enrollment":176,"completionDate":"2028-05-30"},{"nctId":"NCT03330847","phase":"PHASE2","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-07","conditions":["Metastatic Triple Negative Breast Cancer"],"enrollment":273,"completionDate":"2026-09-04"},{"nctId":"NCT07460180","phase":"PHASE1,PHASE2","title":"The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-05-01","conditions":["Ovarian Cancer","Epithelial Cancer","Fallopian Tube Cancer"],"enrollment":55,"completionDate":"2032-05-01"},{"nctId":"NCT03660826","phase":"PHASE2","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-27","conditions":["Endometrial Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma","Endometrial Serous Adenocarcinoma","Endometrial Undifferentiated Carcinoma","Endometrioid Adenocarcinoma","Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8"],"enrollment":288,"completionDate":"2027-01-21"},{"nctId":"NCT07453394","phase":"PHASE1,PHASE2","title":"QLS5132 Combination Therapy in Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-04","conditions":["Gastric Cancer (GC)","Non-small Cell Lung Cancer (NSCLC)","Endometrial Cancer","Advanced Solid Tumors","Ovarian Cancer"],"enrollment":626,"completionDate":"2029-02"},{"nctId":"NCT05188508","phase":"PHASE2","title":"Pembrolizumab, Olaparib, and Temozolomide for People With Glioma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-01-14","conditions":["Glioma"],"enrollment":57,"completionDate":"2027-01"},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":["Prostate Cancer","Castrate Sensitive Prostate Cancer","Oligometastatic Disease"],"enrollment":21,"completionDate":"2026-05"},{"nctId":"NCT07454018","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-01","conditions":["Recurrent Ovarian Cancer","Platinum-sensitive Ovarian Cancer"],"enrollment":45,"completionDate":"2029-12-31"},{"nctId":"NCT06909825","phase":"PHASE2","title":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fusion Pharmaceuticals Inc.","startDate":"2025-02-26","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":85,"completionDate":"2030-08-12"},{"nctId":"NCT04090567","phase":"PHASE2","title":"Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-28","conditions":["Advanced Breast Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Germline BRCA1 Gene Mutation","Germline BRCA2 Gene Mutation","HER2/Neu Negative","Metastatic Breast Carcinoma","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":["Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fallopian Tube Undifferentiated Carcinoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Tumor","Ovarian Seromucinous Carcinoma","Ovarian Serous Tumor","Ovarian Transitional Cell Carcinoma","Ovarian Undifferentiated Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal Carcinoma"],"enrollment":579,"completionDate":"2026-11-25"},{"nctId":"NCT07371104","phase":"PHASE1","title":"Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer","status":"RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2026-02-20","conditions":["Cancer","Ovarian Cancer"],"enrollment":40,"completionDate":"2027-03"},{"nctId":"NCT02502266","phase":"PHASE2,PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":["Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Fallopian Tube Transitional Cell Carcinoma","Fallopian Tube Undifferentiated Carcinoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Seromucinous Carcinoma","Ovarian Serous Adenocarcinoma","Ovarian Transitional Cell Carcinoma","Ovarian Undifferentiated Carcinoma","Primary Peritoneal Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma"],"enrollment":582,"completionDate":"2026-12-23"},{"nctId":"NCT02345265","phase":"PHASE2","title":"Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-23","conditions":["Fallopian Tube Carcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Ovarian Carcinoma","Ovarian High Grade Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Primary Peritoneal Carcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma"],"enrollment":70,"completionDate":"2026-11-25"},{"nctId":"NCT01116648","phase":"PHASE1,PHASE2","title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-14","conditions":["Fallopian Tube Carcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian High Grade Serous Adenocarcinoma","Ovarian Serous Adenocarcinoma","Ovarian Serous Surface Papillary Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma","Triple-Negative Breast Carcinoma"],"enrollment":155,"completionDate":"2026-11-25"},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":["Fallopian Tube Mucinous Adenocarcinoma","Ovarian Seromucinous Carcinoma","Platinum-Refractory Fallopian Tube Carcinoma","Platinum-Refractory Ovarian Carcinoma","Platinum-Refractory Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Clear Cell Adenocarcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Fallopian Tube High Grade Serous Adenocarcinoma","Recurrent Fallopian Tube Mucinous Adenocarcinoma","Recurrent Fallopian Tube Transitional Cell Carcinoma","Recurrent Fallopian Tube Undifferentiated Carcinoma","Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian High Grade Serous Adenocarcinoma","Recurrent Ovarian Low Grade Serous Adenocarcinoma","Recurrent Ovarian Mucinous Adenocarcinoma","Recurrent Ovarian Seromucinous Carcinoma","Recurrent Ovarian Transitional Cell Carcinoma","Recurrent Ovarian Undifferentiated Carcinoma","Recurrent Platinum-Resistant Fallopian Tube Carcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Clear Cell Adenocarcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma","Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma","Recurrent Primary Peritoneal Transitional Cell Carcinoma","Recurrent Primary Peritoneal Undifferentiated Carcinoma","Refractory Fallopian Tube Clear Cell Adenocarcinoma","Refractory Fallopian Tube Endometrioid Adenocarcinoma","Refractory Fallopian Tube High Grade Serous Adenocarcinoma","Refractory Fallopian Tube Mucinous Adenocarcinoma","Refractory Fallopian Tube Transitional Cell Carcinoma","Refractory Fallopian Tube Undifferentiated Carcinoma","Refractory Low Grade Fallopian Tube Serous Adenocarcinoma","Refractory Ovarian Clear Cell Adenocarcinoma","Refractory Ovarian Endometrioid Adenocarcinoma","Refractory Ovarian High Grade Serous Adenocarcinoma","Refractory Ovarian Low Grade Serous Adenocarcinoma","Refractory Ovarian Mucinous Adenocarcinoma","Refractory Ovarian Seromucinous Carcinoma","Refractory Ovarian Transitional Cell Carcinoma","Refractory Ovarian Undifferentiated Carcinoma","Refractory Primary Peritoneal Clear Cell Adenocarcinoma","Refractory Primary Peritoneal Endometrioid Adenocarcinoma","Refractory Primary Peritoneal High Grade Serous Adenocarcinoma","Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma","Refractory Primary Peritoneal Transitional Cell Carcinoma","Refractory Primary Peritoneal Undifferentiated Carcinoma"],"enrollment":120,"completionDate":"2026-11-25"},{"nctId":"NCT04024254","phase":"PHASE4","title":"A Study of Serum Folate Levels in Patients Treated With Olaparib","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2020-07-21","conditions":["Ovarian Cancer","Breast Cancer","Folic Acid Deficiency"],"enrollment":10,"completionDate":"2025-12-31"},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":["Glioblastoma","Recurrent Glioblastoma"],"enrollment":78,"completionDate":"2027-03-01"},{"nctId":"NCT04191135","phase":"PHASE2","title":"Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-19","conditions":["Triple Negative Breast Neoplasms"],"enrollment":462,"completionDate":"2025-11-26"},{"nctId":"NCT06995833","phase":"","title":"Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing Surveillance","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-19","conditions":["Endometrial Cancer"],"enrollment":50,"completionDate":"2029-06-29"},{"nctId":"NCT04884360","phase":"PHASE3","title":"D9319C00001- 1L OC Mono Global RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":["Ovarian Cancer"],"enrollment":366,"completionDate":"2027-07-27"},{"nctId":"NCT04005690","phase":"EARLY_PHASE1","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-08-01","conditions":["Locally Advanced Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Ductal Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Stage IV Pancreatic Cancer AJCC v8","Unresectable Pancreatic Ductal Adenocarcinoma","Borderline Resectable Pancreatic Ductal Adenocarcinoma","Resectable Pancreatic Ductal Adenocarcinoma"],"enrollment":90,"completionDate":"2028-02-01"},{"nctId":"NCT04742075","phase":"PHASE2","title":"Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","startDate":"2021-12-15","conditions":["Ovarian Cancer"],"enrollment":188,"completionDate":"2030-12-31"},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma"],"enrollment":24,"completionDate":"2024-12-23"},{"nctId":"NCT02787642","phase":"PHASE1","title":"A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2016-01","conditions":["Soft-tissue Sarcoma"],"enrollment":41,"completionDate":"2022-05"},{"nctId":"NCT04417062","phase":"PHASE2","title":"Olaparib With Ceralasertib in Recurrent Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-24","conditions":["Osteosarcoma","Osteosarcoma Recurrent"],"enrollment":63,"completionDate":"2026-06-01"},{"nctId":"NCT07382544","phase":"PHASE1","title":"Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-12","conditions":["Advanced Cancer","Solid Tumor"],"enrollment":36,"completionDate":"2032-01-31"},{"nctId":"NCT03976323","phase":"PHASE3","title":"Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":["Carcinoma, Nonsquamous Non-small-cell Lung"],"enrollment":1003,"completionDate":"2026-01-29"},{"nctId":"NCT03943173","phase":"EARLY_PHASE1","title":"Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-06-07","conditions":["BRCA-Mutated Ovarian Carcinoma","BRCA1 Gene Mutation","BRCA2 Gene Mutation","High Grade Fallopian Tube Serous Adenocarcinoma","High Grade Ovarian Serous Adenocarcinoma","Primary Peritoneal High Grade Serous Adenocarcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IIIA Fallopian Tube Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Primary Peritoneal Cancer AJCC v8","Stage IIIA1 Fallopian Tube Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Fallopian Tube Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Fallopian Tube Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Primary Peritoneal Cancer AJCC v8","Stage IIIC Fallopian Tube Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Stage IVA Fallopian Tube Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Primary Peritoneal Cancer AJCC v8","Stage IVB Fallopian Tube Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Primary Peritoneal Cancer AJCC v8"],"enrollment":15,"completionDate":"2027-06-27"},{"nctId":"NCT03976362","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":["Carcinoma, Squamous Cell, Non-small-cell Lung"],"enrollment":851,"completionDate":"2026-01-30"},{"nctId":"NCT06572735","phase":"","title":"Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2024-09-24","conditions":["Ovarian Cancer"],"enrollment":50,"completionDate":"2028-01-23"},{"nctId":"NCT03641755","phase":"PHASE1","title":"Olaparib + Sapacitabine in BRCA Mutant Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-10-01","conditions":["Breast Cancer"],"enrollment":10,"completionDate":"2026-10-22"},{"nctId":"NCT02264678","phase":"PHASE1,PHASE2","title":"Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-10-31","conditions":["Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer"],"enrollment":357,"completionDate":"2026-06-30"},{"nctId":"NCT04065269","phase":"PHASE2","title":"ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-11-27","conditions":["Gynaecological Cancers"],"enrollment":174,"completionDate":"2026-08"},{"nctId":"NCT03212274","phase":"PHASE2","title":"Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-30","conditions":["Advanced Malignant Solid Neoplasm","Glioblastoma","Recurrent Cholangiocarcinoma","Recurrent Glioma","Recurrent Malignant Solid Neoplasm","WHO Grade 2 Glioma","WHO Grade 3 Glioma"],"enrollment":89,"completionDate":"2026-07-28"},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":["Early Triple Negative Breast Cancer"],"enrollment":0,"completionDate":"2031-03-18"},{"nctId":"NCT03317392","phase":"PHASE1,PHASE2","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-04","conditions":["Castration-Resistant Prostate Carcinoma","Metastatic Prostate Adenocarcinoma","Stage IVB Prostate Cancer AJCC v8"],"enrollment":145,"completionDate":"2027-02-16"},{"nctId":"NCT06890273","phase":"","title":"NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-20","conditions":["Endometrial Cancer"],"enrollment":150,"completionDate":"2028-09-30"},{"nctId":"NCT03742895","phase":"PHASE2","title":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-12","conditions":["Advanced Solid Neoplasms"],"enrollment":326,"completionDate":"2026-06-30"},{"nctId":"NCT03579316","phase":"PHASE2","title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-07","conditions":["Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma"],"enrollment":96,"completionDate":"2026-12-31"},{"nctId":"NCT04666740","phase":"PHASE2","title":"A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-12-18","conditions":["Metastatic Pancreatic Ductal Adenocarcinoma","Homologous Recombination Deficiency (HRD)"],"enrollment":63,"completionDate":"2027-01"},{"nctId":"NCT04780945","phase":"PHASE2","title":"Functional Analysis of BRCAness","status":"TERMINATED","sponsor":"Leiden University Medical Center","startDate":"2019-01-21","conditions":["Ovarian Neoplasm Epithelial","Homologous Recombination Deficiency","BRCA1 Mutation","BRCA2 Mutation"],"enrollment":27,"completionDate":"2024-12-31"},{"nctId":"NCT03263650","phase":"PHASE2","title":"Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-03","conditions":["Prostate Cancer Aggressiveness","Prostate Carcinoma"],"enrollment":96,"completionDate":"2026-06-30"},{"nctId":"NCT04683679","phase":"PHASE2","title":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-21","conditions":["Triple Negative Breast Cancer","TNBC - Triple-Negative Breast Cancer","Breast Cancer","Metastatic Breast Cancer"],"enrollment":34,"completionDate":"2027-01"},{"nctId":"NCT02032823","phase":"PHASE3","title":"Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2014-04-22","conditions":["Breast Cancer"],"enrollment":1836,"completionDate":"2029-05-28"},{"nctId":"NCT02861573","phase":"PHASE1,PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":["Metastatic Castration-Resistant Prostate Cancer"],"enrollment":1200,"completionDate":"2028-07-24"},{"nctId":"NCT02000622","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"startDate":"2014-03-27","conditions":["Breast Cancer Metastatic","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation"],"enrollment":302,"completionDate":"2025-12-23"},{"nctId":"NCT07407452","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2026-02-01","conditions":["Ovarian Cancers"],"enrollment":50,"completionDate":"2028-12-31"},{"nctId":"NCT03085147","phase":"PHASE1,PHASE2","title":"A Dye for the Detection of Cancer of the Tongue and Mouth","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-03-15","conditions":["Oral Squamous Cell Carcinoma (OSCC)"],"enrollment":23,"completionDate":"2026-07"},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":["Breast Cancer"],"enrollment":200,"completionDate":"2030-06"},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":["Breast Cancer","Oligometastasis","Metastatic Breast Cancer"],"enrollment":340,"completionDate":"2032-10-31"},{"nctId":"NCT05238922","phase":"PHASE1","title":"Study of INCB123667 in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2022-07-05","conditions":["Solid Tumors"],"enrollment":604,"completionDate":"2027-08-31"},{"nctId":"NCT03775486","phase":"PHASE2","title":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-21","conditions":["Non-small Cell Lung Cancer NSCLC"],"enrollment":401,"completionDate":"2026-09-27"},{"nctId":"NCT03155620","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-07-31","conditions":["Advanced Malignant Solid Neoplasm","Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Histiocytic Sarcoma","Juvenile Xanthogranuloma","Langerhans Cell Histiocytosis","Malignant Glioma","Recurrent Childhood Rhabdomyosarcoma","Recurrent Ependymoma","Recurrent Ewing Sarcoma","Recurrent Glioma","Recurrent Hepatoblastoma","Recurrent Langerhans Cell Histiocytosis","Recurrent Malignant Germ Cell Tumor","Recurrent Malignant Solid Neoplasm","Recurrent Medulloblastoma","Recurrent Neuroblastoma","Recurrent Non-Hodgkin Lymphoma","Recurrent Osteosarcoma","Recurrent Peripheral Primitive Neuroectodermal Tumor","Recurrent Primary Central Nervous System Neoplasm","Recurrent Rhabdoid Tumor","Recurrent Soft Tissue Sarcoma","Refractory Ewing Sarcoma","Refractory Glioma","Refractory Hepatoblastoma","Refractory Langerhans Cell Histiocytosis","Refractory Malignant Germ Cell Tumor","Refractory Malignant Solid Neoplasm","Refractory Medulloblastoma","Refractory Neuroblastoma","Refractory Non-Hodgkin Lymphoma","Refractory Osteosarcoma","Refractory Peripheral Primitive Neuroectodermal Tumor","Refractory Primary Central Nervous System Neoplasm","Refractory Rhabdoid Tumor","Refractory Rhabdomyosarcoma","Rhabdoid Tumor","Stage III Osteosarcoma AJCC v7","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Osteosarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Stage IVA Osteosarcoma AJCC v7","Stage IVB Osteosarcoma AJCC v7","Wilms Tumor"],"enrollment":1376,"completionDate":"2027-01-06"},{"nctId":"NCT06331559","phase":"PHASE1","title":"Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2024-03-19","conditions":["Advanced Solid Tumors"],"enrollment":13,"completionDate":"2025-09-17"},{"nctId":"NCT03851614","phase":"PHASE2","title":"Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-08","conditions":["Mismatch Repair Proficient Colorectal Cancer","Pancreatic Adenocarcinoma","Leiomyosarcoma"],"enrollment":90,"completionDate":"2027-01-01"},{"nctId":"NCT03025035","phase":"PHASE2","title":"Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer","status":"COMPLETED","sponsor":"Yuan Yuan","startDate":"2017-09-10","conditions":["Breast Cancer"],"enrollment":14,"completionDate":"2025-11-21"},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":["Triple Negative Breast Cancer"],"enrollment":81,"completionDate":"2029-02-15"},{"nctId":"NCT01081951","phase":"PHASE2","title":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2010-02-04","conditions":["Ovarian Cancer"],"enrollment":162,"completionDate":"2026-12-31"},{"nctId":"NCT03008278","phase":"PHASE1,PHASE2","title":"Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-06","conditions":["Metastatic Esophageal Carcinoma","Metastatic Gastric Carcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Recurrent Esophageal Carcinoma","Recurrent Gastric Carcinoma","Recurrent Gastroesophageal Junction Adenocarcinoma","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Unresectable Esophageal Carcinoma","Unresectable Gastric Carcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma"],"enrollment":51,"completionDate":"2025-08-13"},{"nctId":"NCT05432791","phase":"PHASE2,PHASE3","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-30","conditions":["Locally Advanced Uterine Corpus Leiomyosarcoma","Metastatic Uterine Corpus Leiomyosarcoma","Stage III Uterine Corpus Leiomyosarcoma AJCC v8","Stage IV Uterine Corpus Leiomyosarcoma AJCC v8","Unresectable Uterine Corpus Leiomyosarcoma"],"enrollment":73,"completionDate":"2027-01-30"},{"nctId":"NCT06177171","phase":"PHASE1","title":"Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors","status":"RECRUITING","sponsor":"Pamela Munster","startDate":"2024-02-07","conditions":["BRCA1 Mutation","BRCA2 Mutation","BRCA Mutation","PALB2 Gene Mutation","Checkpoint Kinase 2 Gene Mutation","ATM Gene Mutation"],"enrollment":18,"completionDate":"2028-01-31"},{"nctId":"NCT05568550","phase":"PHASE2","title":"Pembro With Radiation With or Without Olaparib","status":"RECRUITING","sponsor":"Zin W Myint","startDate":"2023-07-27","conditions":["Prostate Cancer"],"enrollment":64,"completionDate":"2029-07-02"}],"_emaApprovals":[{"date":"2014-10-23","status":"Authorised","company":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT01844986","NCT02477644","NCT01874353","NCT00753545","NCT02000622","NCT02184195","NCT02987543"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Lynparza"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000191291","MMSL":"231537","NDDF":"015824","UNII":"WOH1JD9AR8","VUID":"4034034","CHEBI":"CHEBI:83766","VANDF":"4034034","INN_ID":"8685","RXNORM":"1597582","UMLSCUI":"C2316164","chemblId":"CHEMBL521686","ChEMBL_ID":"CHEMBL521686","KEGG_DRUG":"D09730","DRUGBANK_ID":"DB09074","PDB_CHEM_ID":" 09L","PUBCHEM_CID":"23725625","SNOMEDCT_US":"432162002","IUPHAR_LIGAND_ID":"7519","MESH_SUPPLEMENTAL_RECORD_UI":"C531550"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"AstraZeneca Pharmaceuticals LP","brandName":"Lynparza","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"AstraZeneca","relationship":"Original Developer"},{"period":"present","companyName":"Astrazeneca","relationship":"Current Owner"},{"period":"2018","companyName":"AstraZeneca KK","relationship":"PMDA Licensee"}],"publicationCount":3828,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:57:22.299233+00","atcClassification":{"source":"DrugCentral","atcCode":"L01XK01","allCodes":["L01XK01"]},"biosimilarFilings":[],"originalDeveloper":"Astrazeneca Pharms","recentPublications":[{"date":"2026 Mar 20","pmid":"41900138","title":"Epacadostat and Olaparib Synergistically Inhibit the Growth of BRCA-Proficient Triple-Negative Breast Cancer by Suppressing the Expression of BRCA1 and RAD51.","journal":"Molecules (Basel, Switzerland)"},{"date":"2026 Mar 12","pmid":"41900056","title":"Four New Menadione Thioderivatives, Potential Antineoplastic Candidates: In Silico and PARP-1 Inhibition Studies.","journal":"Molecules (Basel, Switzerland)"},{"date":"2026 Mar 10","pmid":"41899447","title":"MOB2 Loss Sensitizes Lung Cancer Cells to PARP Inhibition Through p53-Dependent DNA Damage Signaling.","journal":"Current issues in molecular biology"},{"date":"2026 Mar 9","pmid":"41899441","title":"MSTN and TCF12 as Candidate Immunometabolic Signatures in Glioma-Associated Foam Cells: Insights from Integrated Multi-Omics Analysis.","journal":"Current issues in molecular biology"},{"date":"2026 Mar 19","pmid":"41898642","title":"The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma.","journal":"International journal of molecular sciences"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"active","companyName":"Astrazeneca","companyId":"astrazeneca","modality":"Small Molecule","firstApprovalDate":"2014","enrichmentLevel":4,"visitCount":7,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-09-12T00:00:00.000Z","mah":"ASTRAZENECA","brand_name_local":null,"application_number":"NDA208558"},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":131,"withResults":48},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:16.900372+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}